Pathogenesis, Symptomatology, and Transmission of SARS-CoV-2 through analysis of Viral Genomics and Structure
Halie M. Rando, Adam L. MacLean, Alexandra J. Lee, Sandipan Ray, Vikas Bansal, Ashwin N. Skelly, Elizabeth Sell, John J. Dziak, Lamonica Shinholster, Lucy D'Agostino McGowan, Marouen Ben Guebila, Nils Wellhausen, Sergey Knyazev, Simina M. Boca, Stephen Capone, Yanjun Qi, YoSon Park, Yuchen Sun, David Mai, Christian Brueffer, James Brian Byrd, Jinhui Wang, Ronan Lordan, Ryan Velazquez, Gregory L Szeto, John P. Barton, Rishi Raj Goel, Serghei Mangul, Tiago Lubiana, COVID-19 Review Consortium, Anthony Gitter, Casey S. Greene
PPathogenesis, Symptomatology, and Transmission of SARS-CoV-2 through analysis of Viral Genomics and Structure
This manuscript (permalink) was automatically generated from greenelab/covid19-review@7d93765 on February 12, 2021. It represents one section of a larger evolving review on SARS-CoV-2 and COVID-19 available at https://greenelab.github.io/covid19-review/
This in progress manuscript is not intended for the general public.
This is a review paper that is authored by scientists for an audience of scientists to discuss research that is in progress. If you are interested in guidelines on testing, therapies, or other issues related to your health, you should not use this document. Instead, you should collect information from your local health department, the CDC’s guidance, or your own government.
Authors • Halie M. Rando
Adam L. MacLean
Alexandra J. Lee
Sandipan Ray
Vikas Bansal
Ashwin N. Skelly
Elizabeth Sell
John J. Dziak
Lamonica Shinholster
Lucy D'Agostino McGowan
Marouen Ben Guebila
Nils Wellhausen
Sergey Knyazev
Simina M. Boca
Stephen Capone
Yanjun Qi
YoSon Park yoson
Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America · Funded by NHGRI R01 HG10067 •
Yuchen Sun kevinsunofficial Department of Computer Science, University of Virginia, Charlottesville, VA, United States of America •
David Mai
Christian Brueffer
James Brian Byrd
Jinhui Wang
Ronan Lordan
Ryan Velazquez
Gregory L Szeto
John P. Barton
Rishi Raj Goel https://orcid.org/0000-0003-1715-5191 rishirajgoel rishirajgoel Institute for Immunology, University of Pennsylvania, Philadelphia, PA, United States of America •
Serghei Mangul
Tiago Lubiana
COVID-19 Review Consortium • Anthony Gitter
Casey S. Greene
COVID-19 Review Consortium:
Vikas Bansal, John P. Barton, Simina M. Boca, Christian Brueffer, James Brian Byrd, Stephen Capone, Shikta Das, Anna Ada Dattoli, John J. Dziak, Jeffrey M. Field, Soumita Ghosh, Anthony Gitter, Rishi Raj Goel, Casey S. Greene, Marouen Ben Guebila, Fengling Hu, Nafisa M. Jadavji, Sergey Knyazev, Likhitha Kolla, Alexandra J. Lee, Ronan Lordan, Tiago Lubiana, Temitayo Lukan, Adam L. MacLean, David Mai, Serghei Mangul, David Manheim, Lucy D'Agostino McGowan, YoSon Park, Dimitri Perrin, Yanjun Qi, Diane N. Rafizadeh, Bharath Ramsundar, Halie M. Rando, Sandipan Ray, Michael P. Robson, Elizabeth Sell, Lamonica Shinholster, Ashwin N. Skelly, Yuchen Sun, Gregory L Szeto, Ryan Velazquez, Jinhui Wang, Nils Wellhausen Authors with similar contributions are ordered alphabetically.
Abstract
The novel coronavirus SARS-CoV-2, which emerged in late 2019, has since spread around the world infecting tens of millions of people with coronavirus disease 2019 (COVID-19). While this viral species was unknown prior to January 2020, its similarity to other coronaviruses that infect humans has allowed for rapid insight into the mechanisms that it uses to infect human hosts, as well as the ways in which the human immune system can respond. Here, we contextualize SARS-CoV-2 among other coronaviruses and identify what is known and what can be inferred about its behavior once inside a human host. Because the genomic content of coronaviruses, which specifies the virus’s structure, is highly conserved, early genomic analysis provided a significant head start in predicting viral pathogenesis. The pathogenesis of the virus offers insights into symptomatology, transmission, and individual susceptibility. Additionally, prior research into interactions between the human immune system and coronaviruses has identified how these viruses can evade the immune system’s protective mechanisms. We also explore systems-level research into the regulatory and proteomic effects of SARS-CoV-2 infection and the immune response. Understanding the structure and behavior of the virus serves to contextualize the many facets of the COVID-19 pandemic and can influence efforts to control the virus and treat the disease.
Importance
COVID-19 involves a number of organ systems and can present with a wide range of symptoms. Understanding how the virus infects epithelial cells, however, serves to contextualize how these systems connect. Similarly, while the modes of viral transmission have been under debate throughout much of 2020 and the beginning of 2021, the available research suggests that these patterns are very similar to those seen in the closely related viruses SARS-CoV-1 and possibly MERS-CoV. Exploring the structure, phylogeny, and pathogenesis of the virus therefore helps to guide interpretation of the broader impacts of the virus on the human body and on human populations. For this reason, an in-depth exploration of viral mechanisms is critical to a robust understanding of the COVID-19 pandemic. ntroduction
The current coronavirus disease 2019 (COVID-19) pandemic, caused by the
Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) virus, represents an acute global health crisis. Symptoms of the disease can range from mild to severe or fatal [1] and can affect a variety of organs and systems [2]. Outcomes of infection can include acute respiratory distress (ARDS) and acute lung injury, as well as damage to other organ systems [2,3]. Understanding the progression of the disease, including these diverse symptoms, depends on understanding how the virus interacts with the host. Additionally, the fundamental biology of the virus can provide insights into how it is transmitted among people, which can, in turn, inform efforts to control its spread. As a result, a thorough understanding of the pathogenesis of SARS-CoV-2 is a critical foundation on which to build an understanding of COVID-19 and the pandemic as a whole. The rapid identification and release of the genomic sequence of the virus in January 2020 [4] provided early insight into the virus in a comparative genomic context. The viral genomic sequence clusters with known coronaviruses (order
Nidovirales , family
Coronaviridae , subfamily
Orthocoronavirinae ). Phylogenetic analysis of the coronaviruses reveals four major subclades, each corresponding to a genus: the alpha, beta, gamma, and delta coronaviruses. Among them, alpha- and betacoronaviruses infect mammalian species, gammacoronaviruses infect avian species, and deltacoronaviruses infect both mammalian and avian species [5]. The novel virus now known as SARS-CoV-2 was identified as a betacoronavirus belonging to the B lineage based on phylogenetic analysis of a polymerase chain reaction (PCR) amplicon fragment from five patients along with the full genomic sequence [6]. This lineage also includes the
Severe acute respiratory syndrome-related coronavirus (SARS-CoV-1) that caused the 2002-2003 outbreak of Severe Acute Respiratory Syndrome (SARS) in humans [6]. Because viral structure and mechanisms of pathogenicity are highly conserved within the order, this phylogenetic analysis provided a basis for forming hypotheses about how the virus interacts with hosts, including which tissues, organs, and systems would be most susceptible to SARS-CoV-2 infection. Coronaviruses that infect humans (HCoV) are not common, but prior research into other HCoV such as SARS-CoV-1 and
Middle East respiratory syndrome-related coronavirus (MERS-CoV), as well as other viruses infecting humans such as a variety of influenza species, established a strong foundation that accelerated the pace of SARS-CoV-2 research. Coronaviruses are large viruses that can be identified by their distinctive “crown-like” shape (Figure 1). Their spherical virions are made from lipid envelopes ranging from 100 to 160 nanometers in which peplomers (protruding structures) of two to three spike (S) glycoproteins are anchored, creating the crown [7,8]. These spikes, which are critical to both viral pathogenesis and to the response by the host immune response, have been visualized using cryo-electron microscopy [9]. Because they induce the human immune response, they are also the target of many proposed therapeutic agents. Viral pathogenesis is typically broken down into three major components: entry, replication, and spread [10]. However, in order to draw a more complete picture of pathogenesis, it is also necessary to examine how infection manifests clinically, identify systems-level interactions between the virus and the human body, and consider the possible effects of variation or evolutionary change on pathogenesis and virulence. hus, clinical medicine and traditional biology are both important pieces of the puzzle of SARS-CoV-2 presentation and pathogenesis.
Coronavirus Structure and Pathogenesis
Structure of Coronaviruses
Genome structure is highly conserved among coronaviruses, meaning that the relationship between the SARS-CoV-2 genome and its pathogenesis can be inferred from prior research in related viral species. The genomes of viruses in the
Nidovirales order share several fundamental characteristics. They are non-segmented, which means the viral genome is contained in a single capsid, and are enveloped, which means that the genome and capsid are encased by a lipid bilayer. Coronaviruses have large positive-sense RNA (ssRNA+) genomes ranging from 27 to 32 kilobases in length [11,12]. The SARS-CoV-2 genome lies in the middle of this range at 29,903 bp [12]. Genome organization is highly conserved within the order [11]. There are three major genomic regions: one containing the replicase gene, one containing the genes encoding structural proteins, and interspersed accessory genes [11] (Figure 1). The replicase gene comprises about two-thirds of the genome and consists of two open reading frames that are translated with ribosomal frameshifting [11]. This polypeptide is then translated into 16 non-structural proteins (nsp), except in gammacoronaviruses where nsp1 is absent, that form replication machinery used to synthesize viral RNA [13]. The remaining third of the genome encodes structural proteins, including the spike, membrane, envelope, and nucleocapsid proteins. Additional accessory genes are sometimes present between these two regions, depending on the species or strain. Much attention has been focused on the S protein, which is a critical structure involved in cell entry.
Figure 1:
Structure of SARS-CoV-2 capsid and genome.
A) The genomic structure of coronaviruses is highly conserved and includes three main regions. Open reading frames (ORF) 1a and 1b contain two polyproteins that encode the non-structural proteins (nsp). The nsp include proteases such as RNA-dependent RNA Polymerase (RdRp). The last third of the genome encodes structural proteins, including the spike (S), envelope (E), membrane (M) and nucleocapsid (N) proteins. Accessory genes can also be interspersed throughout the genome [11]. B) The physical structure of the coronavirus virion, including the components determined by the conserved structural proteins S, E, M and N.
Pathogenic Mechanisms of Coronaviruses
While, like most viruses, it is possible that SARS-CoV-1 and SARS-CoV-2 can enter cells through endocytosis, coronaviruses are also able to target cells for entry through fusion with the plasma membrane [14,15]. This process is conserved among coronaviruses and is closely associated with the content of their genomes. Cell entry proceeds in three steps: binding, cleavage, and fusion. First, the viral spike protein binds to a host cell via a recognized receptor or entry point. Coronaviruses can bind to a range of host receptors [16,17], with binding conserved only at the genus level [5]. Viruses in the betacoronavirus genus, to which SARS-CoV-2 belongs, are known to bind to the CEACAM1 protein, 5-N-acetyl-9-O-acetyl neuraminic acid, and to the angiotensin-converting enzyme 2 (ACE2) [16]. SARS-CoV-2 has a high affinity for human ACE2, which is expressed in the vascular epithelium, other epithelial cells, and cardiovascular and renal tissues [18,19], as well as many others [20]. The binding process is uided by the molecular structure of the spike protein, which is structured in three segments: an ectodomain, a transmembrane anchor, and an intracellular tail [21]. The ectodomain forms the crown-like structures on the viral membrane and contains two subdomains known as the S1 and S2 subunits [22]. The S1 (N-terminal) domain forms the head of the crown and contains the receptor binding motif, and the S2 (C-terminal) domain forms the stalk that supports the head [22]. The S1 subunit guides the binding of the virus to the host cell, and the S2 subunit guides the fusion process [21]. After the binding of the S1 subunit to an entry point, the spike protein is often cleaved at the S1-S2 boundary by a host protease [23,24,25]. Similar to SARS-CoV-1, SARS-CoV-2 exhibits redundancy in which host proteases can cleave the S protein [26]. Specifically, both transmembrane protease serine protease-2 (TMPRSS2) and cathepsins B/L have been shown to mediate SARS-CoV-2 S protein proteolytic priming, and small molecule inhibition of these enzymes fully inhibited viral entry in vitro [26,27]. Proteolytic priming prepares the S protein for fusion [24,25]. The two subunits remain bound by van der Waals forces, with the S1 subunit stabilizing the S2 subunit during the membrane fusion process [23]. Electron microscopy suggests that in some coronaviruses, including SARS-CoV-1 and MERS-CoV, a six-helix bundle separates the two subunits in the postfusion conformation, and the unusual length of this bundle facilitates membrane fusion through the release of additional energy [5]. Cleavage at a second site within S2 by these same proteases activates S for fusion by inducing conformational changes [23]. The viral membrane can then fuse with the endosomal membrane to release the viral genome into the host cytoplasm. Once the virus enters a host cell, the replicase gene is translated and assembled into the viral replicase complex. This complex then synthesizes the double-stranded RNA (dsRNA) genome from the genomic ssRNA(+). The dsRNA genome is transcribed and replicated to create viral mRNAs and new ssRNA(+) genomes [11,28]. From there, the virus can spread into other cells. In this way, the genome of SARS-CoV-2 provides insight into the pathogenic behavior of the virus. Immune Evasion Strategies
Research in other HCoV provides some indication of how SARS-CoV-2 infection proceeds in spite of the human immune response. By infecting the epithelium, viruses such as SARS-CoV-1 are known to bypass the physical barriers, such as skin and mucus, that comprise the immune system’s first line of defense [29]. Once the virus infiltrates host cells, it is adept at evading detection. CD163+ and CD68+ macrophage cells are especially crucial for the establishment of SARS-CoV-1 in the body [29]. These cells most likely serve as viral reservoirs that help shield SARS-CoV-1 from the innate immune response. According to a study on the viral dissemination of SARS-CoV-1 in Chinese macaques, viral RNA could be detected in some monocytes throughout the process of differentiation into dendritic cells [29]. This lack of active viral replication allows SARS-CoV-1 to escape the innate immune response because reduced levels of detectable viral RNA allow the virus to avoid both natural killer cells and Toll-like receptors [29]. Even during replication, SARS-CoV-1 is able to mask its dsRNA genome from detection by the immune system. Although dsRNA is a pathogen-associated molecular pattern that would typically initiate a response from the innate immune system [30], in vitro analysis of nidoviruses including SARS-CoV-1 suggests that these viruses can induce the development of double-membrane vesicles that protect the dsRNA signature from being detected by the host immune ystem [31]. This protective envelope can therefore insulate these coronaviruses from the innate immune system’s detection mechanism [32]. HCoVs are also known to interfere with the host immune response, rather than just evade it. For example, the virulence of SARS-CoV-2 is increased by nsp1, which can suppress host gene expression by stalling mRNA translation and inducing endonucleolytic cleavage and mRNA degradation [33]. SARS-CoV-1 also evades the immune response by interfering with type I IFN induction signaling, which is a mechanism that leads to cellular resistance to viral infections. SARS-CoV-1 employs methods such as ubiquitination and degradation of RNA sensor adaptor molecules MAVS and TRAF3/6 [34]. Also, MERS-CoV downregulates antigen presentation via MHC class I and MHC class II, which leads to a reduction in T cell activation [34]. These evasion mechanisms, in turn, can facilitate systemic infection. Coronaviruses such as SARS-CoV-1 are also able to evade the humoral immune response through other mechanisms, such as inhibiting certain cytokine pathways or down-regulating antigen presentation by the cells [31].
Host Cell Susceptibility
ACE2 and TMPRSS2 have been identified as the primary entry portal and as a critical protease, respectively, in facilitating the entry of SARS-CoV-1 and SARS-CoV-2 into a target cell [9,26,35,36,37]. This finding has led to a hypothesized role for ACE2 and TMPRSS2 expression in determining which cells, tissues, and organs are most likely to be infected by SARS-CoV-2. ACE2 is expressed in numerous organs, such as the heart, kidney, and intestine, but it is most prominently expressed in alveolar epithelial cells; this pattern of expression is expected to contribute to the virus’ association with lung pathology [18,38,39] as well as that of SARS [40]. Clinical investigations of COVID-19 patients have detected SARS-CoV-2 transcripts in bronchoalveolar lavage fluid (BALF) (93% of specimens), sputum (72%), nasal swabs (63%), fibrobronchoscopy brush biopsies (46%), pharyngeal swabs (32%), feces (29%), and blood (1%) [41]. Two studies reported that SARS-CoV-2 could not be detected in urine specimens [41,42]; however, a third study identified four urine samples (out of 58) that were positive for SARS-CoV-2 nucleic acids [43]. Although respiratory failure remains the leading cause of death for COVID-19 patients [44], SARS-CoV-2 infection can damage many other organ systems including the heart [45], kidneys [46,47], liver [48], and gastrointestinal tract [49,50]. As it becomes clear that SARS-CoV-2 infection can damage multiple organs, the scientific community is pursuing multiple avenues of investigation in order to build a consensus about how the virus affects the human body.
Clinical Presentation of COVID-19
SARS-CoV-2 pathogenesis is closely linked with the clinical presentation of the COVID-19 disease. Reports have described diverse symptom profiles associated with COVID-19, with a great deal of variability both within and between institutions and regions. A large study from Wuhan, China conducted early in the pandemic identified fever and cough as the two most common symptoms that patients reported at hospital admission [51], while a retrospective study in China described the clinical presentations of patients infected with SARS-CoV-2 as including lower respiratory tract infection with fever, dry cough, and dyspnea (shortness of breath) [52]. This study [52] noted that upper respiratory tract symptoms were less common, suggesting that he virus preferentially targets cells located in the lower respiratory tract. However, data from the New York City region [53,54] showed variable rates of fever as a presenting symptom, suggesting that symptoms may not be consistent across individuals. For example, even within New York City, one study [53] identified low oxygen saturation (<90% without the use of supplemental oxygen or ventilation support) in 20.4% of patients upon presentation, with fever being present in 30.7%, while another study [51] reported cough (79.4%), fever (77.1%), and dyspnea (56.5%) as the as the most common presenting symptoms; both of these studies considered only hospitalized patients. A later study reported radiographic findings such as ground-glass opacity and bilateral patchy shadowing in the lungs of many hospitalized patients, with most COVID-19 patients having lymphocytopenia, or low levels of lymphocytes (a type of white blood cell) [51]. Patients may also experience loss of smell, myalgias (muscle aches), fatigue, or headache. Gastrointestinal symptoms can also present [55], and the CDC includes nausea and vomiting, as well congestion and runny nose, on its list of symptoms consistent with COVID-19 [1]. A preprint using data from an app-based survey of 500,000 individuals in the US found that among those tested for SARS-CoV-2, a loss of taste or smell, fever, and a cough were significant predictors of a positive test result [56]. It is important to note that in this study, the predictive value of symptoms may be underestimated if they are not specific to COVID-19. This underestimation could occur because the outcome measured was a positive, as opposed to a negative, COVID-19 test result, meaning an association would be more easily identified for symptoms that were primarily or exclusively found with COVID-19. At the time the surveys were conducted, due to limits in US testing infrastructure, respondents typically needed to have some symptoms known to be specific to COVID-19 in order to qualify for testing. Widespread testing of asymptomatic individuals may therefore provide additional insight into the range of symptoms associated with COVID-19. Consistent with the wide range of symptoms observed and the pathogenic mechanisms described above, COVID-19 can affect diverse body systems in addition to causing respiratory problems [57]. For example, COVID-19 can lead to acute kidney injury, especially in patients with severe respiratory symptoms or certain preexisting conditions [58]. It can also cause neurological complications [59,60], potentially including stroke, seizures or meningitis [61,62]. In fact, autopsy samples suggest that SARS-CoV-2 may be able to enter the central nervous system via the neural–mucosal interface [63]. COVID-19 has also been associated with an increased incidence of large vessel stroke, particularly in patients under the age of 40 [64], and other thrombotic events including pulmonary embolism and deep vein thrombosis [65]. The mechanism behind these complications has been suggested to be related to coagulopathy, with reports indicating the presence of antiphospholipid antibodies [66] and elevated levels of d-dimer and fibrinogen degradation products in deceased patients [67]. Other viral infections have been associated with coagulation defects and changes to the coagulation cascade; notably, SARS was also found to lead to disseminated intravascular coagulation and was associated with both pulmonary embolism and deep vein thrombosis [68]. The mechanism behind these insults has been suggested to be related to inflammation-induced increases in the von Willebrand factor clotting protein, leading to a pro-coagulative state [68]. Abnormal clotting (thromboinflammation or coagulopathy) has been increasingly discussed recently as a possible key mechanism in many cases of severe COVID-19, and may be associated with the high d-dimer levels often observed in severe cases [69,70,71]. This excessive clotting in lung apillaries has been suggested to be related to a dysregulated activation of the complement system, part of the innate immune system [72,73].
Cytokine Release Syndrome
Symptoms of a disease can be caused by a pathogen, but they can also be caused by the immune system’s reaction to the pathogen. A dysregulated immune response can cause significant damage to the host [74,75,76]. The inflammatory response has received particular attention for its role in both a healthy response to infection and a pathogenic one. Inflammation is one of the most visible components of the immune response, as it is responsible for the hallmarks of injury, such as pain, heat, and swelling [77]. In response to injury or to signaling by pattern recognition receptors indicating the detection of a molecular pattern associated with a pathogen or foreign body, the immune system stimulates leukocytes that travel to the site of the threat, where they then produce cytokines [77]. Cytokines are a diverse group of small proteins that play an important role in intercellular signaling [78]. Cytokines can be both pro- and anti-inflammatory, which means they can either stimulate or inhibit the production of additional cytokines [78,79]. Some notable pro-inflammatory cytokines include the interleukins IL-1β and IL-6 and tumor necrosis factor α (TNF-α) [79]. Anti-inflammatory cytokines play an immunoregulatory role complementary to the cascading effect of pro-inflammatory cytokines [78,79]. A number of interleukins and interferons play anti-inflammatory roles, and receptors or receptor antagonists for inflammatory cytokines are also important for regulating inflammation [79]. IL-10 is an anti-inflammatory cytokine of particular note because it regulates the expression of TNF-α, IL-1, and IL-6 [79]. When the pro- and anti-inflammatory responses are both commensurate with the threat posed, the immune system drives a shift back to homeostasis [80]. However, when the responses are disproportionate, the cytokine response can become dysregulated. Too low of an inflammatory response will not eliminate the immune threat [80]. In contrast, if the response is dysregulated towards excessive pro-inflammatory cytokine activity, inflammation can cascade [81] and cause cell damage, among other problems [77]. Elevated levels of inflammation over the long-term are associated with many chronic health conditions, including type 2 diabetes, dementia and Alzheimer’s, and arthritis [82]. On a shorter timescale, dysregulated systemic inflammation can cause sepsis, which can lead to multi-organ failure and death [78,83]. Cytokines have been investigated for their role in the immune response to lung infections long before the COVID-19 pandemic. Dysregulation of the inflammatory response, including elevated levels of pro-inflammatory cytokines, is found in patients with ARDS, which is a severe condition that can arise from pneumonia, SARS, and COVID-19 [81]. One study of patients with and at risk for ARDS, specifically those who were intubated for medical ventilation, found that shortly after the onset of ARDS, anti-inflammatory cytokine concentration in BALF increased relative to the concentration of pro-inflammatory cytokines [84]. The results suggest that an increase in pro-inflammatory cytokines such as IL-6 may signal the onset of ARDS, but recovery depends on an increased anti-inflammatory response [84]. However, patients with severe ARDS were excluded from this study. Acute phase response to an infection can also cause damage to the capillary endothelium, allowing leaks that disrupt the balance between pro-inflammatory cytokines and their regulators [84]. Hyperactivity of the pro-inflammatory response due to lung infection is commonly associated with acute lung injury and more rarely with the more severe anifestation, ARDS [78]. The heightened inflammatory response in the lungs can also serve as a source for systemic inflammation, or sepsis, and potentially multi-organ failure [78]. The shift from local to systemic inflammation is a phenomenon often referred to broadly as a cytokine storm [78] or, more precisely, as cytokine release syndrome [85]. Sepsis is a known possible complication of pneumonia, and in an analysis of over 1,400 US pneumonia patients, IL-6, tumor necrosis factor (TNF), and IL-10 were found to be elevated at intake in patients who developed severe sepsis and/or ultimately deceased [86]. However, unlike the study analyzing pro- and anti-inflammatory cytokines in ARDS patients [84], this study reported that unbalanced pro-/anti-inflammatory cytokine profiles were rare. This discrepancy could be related to the fact that the sepsis study measured only three cytokines. Regardless of variation in the anti-inflammatory response, prior work has therefore made it clear that pulmonary infection and injury are associated with systemic inflammation and with sepsis. While IL-6 is a biomarker sometimes used to assess cytokine storm activity in sepsis [78], the relationship between cytokine profiles and the risks associated with sepsis may be more complex. In fact, although IL-6 has traditionally been considered pro-inflammatory, its pleiotropic effects via both classical and trans-signaling allow it to play an integral role in both the inflammatory and anti-inflammatory responses [87], leading it to be associated with both healthy and pathological responses to viral threat [88]. The inflammatory response was identified early on as a potential driver of COVID-19 outcomes due to existing research in SARS and emerging research in COVID-19. In addition to the known role of cytokines in ARDS and lung infection more broadly, immunohistological analysis at autopsy of patients deceased from SARS revealed that ACE2-expressing cells that were infected by SARS-CoV-1 showed elevated expression of IL-6, IL-1β, and TNF-α [89]. Similarly, the introduction of the S protein from SARS-CoV-1 to mouse macrophages was found to increase production of IL-6 and TNF-α [90]. For SARS-CoV-2 infection leading to COVID-19, early reports described a cytokine storm syndrome-like response in patients with particularly severe infections [38,91,92]. Among patients hospitalized with COVID-19 in Wuhan, China, 112 out of 191 (59%) developed sepsis, including all 54 of the non-survivors [52]. However, the argument has been made that while the cytokine levels observed in COVID-19 patients fall outside of the normal range, they are not as high as typically found in patients with ARDS [93]. Regardless, inflammation has received significant interest both in regards to the pathology of COVID-19 as well as potential avenues for treatment, as the relationship between the cytokine storm and the pathophysiology of COVID-19 has led to the suggestion that a number of immunomodulatory pharmaceutical interventions could hold therapeutic value for the treatment of COVID-19 [94].
Pediatric Presentation
The presentation of COVID-19 infection can vary greatly among pediatric patients and, in some cases, manifests in distinct ways from COVID-19 in adults. Evidence suggests that while children and adolescents tend to have mostly asymptomatic infections, those that are symptomatic typically exhibit a mild illness [95,96,97,98]. One review examined symptoms reported in 17 studies of children infected with COVID-19 during the early months of the COVID-19 epidemic in China and one study from Singapore [99]. In the more than a thousand cases described, the most common reports were for mild symptoms such as fever, dry cough, fatigue, asal congestion and/or runny nose, while three children were reported to be asymptomatic. Severe lower respiratory infection was described in only one of the pediatric cases reviewed. Gastrointestinal symptoms such as vomiting or diarrhea were occasionally reported. Radiologic findings were not always reported in the case studies reviewed, but when they were mentioned they included bronchial thickening, ground-glass opacities, and/or inflammatory lesions [99]. Neurological symptoms have also been reported [100]. These analyses indicate that most pediatric cases of COVID-19 are not severe. Indeed, it is estimated that less than 1% of pediatric cases result in critical illness [97,101]. However, serious complications and, in rare cases, deaths have occurred [102]. Of particular interest, children have occasionally experienced a serious inflammatory syndrome, multisystem inflammatory syndrome in children (MIS-C), following COVID-19 infection. This syndrome is similar in some respects to Kawasaki disease, including Kawasaki disease shock syndrome [103,104,105] and is thought to be a distinct clinical manifestation of SARS-CoV-2 due to its distinct cytokine profile and the presence of burr cells in peripheral blood smears [106,107]. MIS-C has been associated with heart failure in some cases [108]. One case study [109] described an adult who appeared to show symptoms similar to MIS-C after exposure to COVID-19, but cautioned against broad conclusions; a second possible adult case has also been reported [110]. The presentation of SARS-CoV-2 infection is therefore likely to be largely distinct between adult and pediatric populations.
Systems-Level Effects
Systems biology provides a cross-disciplinary analytical paradigm through which the host response to an infection can be analyzed. This field integrates the “omics” fields (genomics, transcriptomics, proteomics, metabolomics, etc.) using bioinformatics and other computational approaches. Over the last decade, systems biology approaches have been used widely to study the pathogenesis of diverse types of life-threatening acute and chronic infectious diseases [111]. Omics-based studies have also provided meaningful information regarding host immune responses and surrogate protein markers in several viral, bacterial and protozoan infections [112]. Though the complex pathogenesis and clinical manifestations of SARS-CoV-2 infection are not yet fully understood, omics technologies offer the opportunity for discovery-driven analysis of biological changes associated with SARS-CoV-2 infection. For example, previous studies suggest that infection by coronaviruses, such as SARS-CoV-1 and MERS-CoV, as well as other viruses, is associated with the upregulation of ACE2. In several preliminary assays and an analysis of microarray data, ACE2 expression was reported to be significantly upregulated following infection of human embryonic kidney cells and human airway epithelial cells [38]. This study also reported that direct stimulation with inflammatory cytokines such as type I interferons (e.g., IFNβ) resulted in the upregulation of ACE2 in human bronchial epithelial cells, with treated groups showing four-fold higher ACE2 expression than control groups at 18 hours post-treatment [38]. While it is still unclear whether SARS-CoV-2 facilitates the positive regulation of its own transmission between host cells, the host immune response itself likely plays a key role in mediating infection-associated pathologies. For this reason, the application of omics technologies to the process of characterizing the host response is expected to provide novel insights into how hosts respond to SARS-CoV-2 infection and how these changes might influence COVID-19 outcomes. ranscriptomics
In addition to the study described above [38], two other studies have profiled expression following SARS-CoV-2 infection using human cell lines. The first study [113] compared transcriptional responses to SARS-CoV-2 and to other respiratory viruses, including MERS-CoV, SARS-CoV,
Human parainfluenza virus 3 , Respiratory syncytial virus , and
Influenza A virus . The responses of three human cell lines were analyzed: A549 (adenocarcinomic human alveolar basal epithelial cells), Calu-3 (human airway epithelial cells derived from human bronchial submucosal glands), and MRC-5 (human fetal lung fibroblast cells). As the viral entry portal ACE2 has low expression in A549 cells, these cells were supplemented with adenovirus-based vectors expressing either mCherry (a fluorescent protein used as a control) or ACE2 (A549-ACE2). The authors also measured host transcriptional responses to SARS-CoV-2 in primary normal human bronchial epithelial cells (HBEC or NHBE cells), nasal washes from an animal model (ferret), and lung samples from two COVID-19 patients. The transcriptional response differed between the COVID-19 infected cells and the cells infected by other viruses, with changes in differential expression specific to each infection type. In the hosts where SARS-CoV-2 was able to replicate efficiently, differential expression analysis revealed that the transcriptional response was significantly different from the response to all of the other viruses tested. A unique pro-inflammatory cytokine signature associated with SARS-CoV-2 was present in cells exposed to both high and low doses of the virus, with the cytokines IL-6 and IL1RA uniquely elevated in response to SARS-CoV-2 relative to other viruses. However, the A549-ACE2 cells showed significant IFN-I or IFN-III expression when exposed to high, but not low, doses of SARS-CoV-2. This finding suggests that IFN induction is dependent on the extent of exposure. Similarly, in cells from the NHBE line, ferrets, and COVID-19 patients, chemokine signaling was significantly enriched, but there was no significant induction of IFN-I or IFN-III. Together, these results suggest that SARS-CoV-2 induces a limited antiviral state with low IFN-I or IFN-III expression and a moderate IFN-stimulated gene response, in contrast to other viruses. Other respiratory viruses have been found to encode antagonists to the IFN response. The analysis of SARS-CoV-2 suggested that this transcriptional state was specific to cells expressing ACE2, as it was not observed in cells lacking expression of this protein except with ACE2 supplementation and at very high (10-fold increase) level of SARS-CoV-2 exposure. This hypothesis was further supported by a recent study [114] that showed that the SARS-CoV-2
ORF3b gene suppresses IFNB1 promoter activity (IFN-I induction) more efficiently than the SARS-CoV-1
ORF3b gene. Taken together, these findings suggest that a unique cytokine profile is associated with the response to the SARS-CoV-2 virus, and that this response differs depending on the extent of exposure. Another study [115] analyzed dynamic transcriptional responses to SARS-CoV-2 and SARS-CoV-1. They characterized the response of three human cell lines, H1299 (human non-small cell lung carcinoma cell line), Calu-3, and Caco-2 (human epithelial colorectal adenocarcinoma cell line), at 4 to 36 hours post infection. Using poly(A) bulk RNA-seq, the authors found negligible susceptibility of H1299 cells (< 0.08 viral read percentage of total reads) compared to Caco-2 and Calu-3 cells (>10% of viral reads). This finding suggests that the risk of infection varies among cell types, and that cell type could influence which hosts are more or less susceptible. Based on visual inspection of microscopy images alongside transcriptional profiling, the authors also showed distinct responses among the host cell lines evaluated. In contrast to aco-2, Calu-3 cells infected with SARS-CoV-2 showed signs of impaired growth and cell death at 24 hours post infection, as well as moderate IFN induction with a strong up-regulation of IFN-stimulated genes. Interestingly, the results were similar to those reported in Calu-3 cells exposed to much higher levels of SARS-CoV-2 [113], as described above. This finding suggests that IFN induction in Calu-3 cells is not dependent on the level of exposure, in contrast to A549-ACE2 cells. The discrepancy could be explained by the observations that Calu-3 cells are highly susceptible to SARS-CoV-2 and show rapid viral replication [27], whereas A549 cells are incompatible with SARS-CoV-2 infection [116]. This discrepancy raises the concern that in vitro models may vary in their similarity to the human response, underscoring the importance of follow-up studies in additional models.
Proteomics
One early proteomics study investigated changes associated with in vitro
SARS-CoV-2 infection using Caco-2 cells [117]. This study reported that SARS-CoV-2 induced alterations in multiple vital physiological pathways, including translation, splicing, carbon metabolism and nucleic acid metabolism in the host cells. Another area of interest is whether SARS-CoV-2 is likely to induce similar changes to other HCoV. For example, because of the high level of sequence homology between SARS-CoV-2 and SARS-CoV-1, it has been hypothesized that sera from convalescent SARS-CoV-1 patients might show some efficacy in cross-neutralizing SARS-CoV-2-S-driven entry [26]. However, despite the high level of sequence homology, certain protein structures might be immunologically distinct, which would be likely to prohibit effective cross-neutralization across different SARS species [118]. Consequently, proteomic analyses of SARS-CoV-1 might also provide some essential information regarding the new pathogen [119,120]. Considering the paucity of omics-level big data sets for SARS-CoV-2 currently available, existing data hubs that contain information for other coronaviruses such as UniProt [121], NCBI Genome Database [122], The Immune Epitope Database and Analysis Resource [123], and The Virus Pathogen Resource [124] will serve as useful resources for comparative bioinformatics research of SARS-CoV-2. Using such databases, the systems-level reconstruction of protein-protein interaction networks will enable the generation of hypotheses about the mechanism of action of SARS-CoV-2 and suggest potential drug targets. In an initial study [125], 26 of the 29 SARS-CoV-2 proteins were cloned and expressed in HEK293T kidney cells, allowing for the identification of 332 high-confidence human proteins interacting with them. Notably, this study suggested that SARS-CoV-2 interacts with innate immunity pathways. Ranking pathogens by the similarity between their interactomes and that of SARS-CoV-2 suggested
West Nile virus , Mycobacterium tuberculosis , and human papillomavirus infections as the top three hits. Therefore, given the lung symptoms associated with COVID-19, the
Mycobacterium tuberculosis host-pathogen interactome in particular might provide new insights to the mechanism of SARS-CoV-2 infection. Additionally, it was suggested that the envelope protein, E, could disrupt host bromodomain-containing proteins, i.e., BRD2 and BRD4, that bind to histones, and the spike protein could likely intervene in viral fusion by modulating the GOLGA7-ZDHHC5 acyl-transferase complex to increase palmitoylation, which is a post-translational modification that affects how proteins interact with membranes [126]. nother study [127] used patient-derived peripheral blood mononuclear cells to identify 251 host proteins targeted by SARS-CoV-2. This study also reported that more than 200 host proteins were disrupted following infection. In particular, a network analysis showed that nsp9 and nsp10 interacted with NF-Kappa-B-Repressing Factor, which encodes a transcriptional repressor that mediates repression of genes responsive to Nuclear Factor kappa-light-chain-enhancer of activated B-cells. These genes are important to pro-, and potentially also anti-, inflammatory signaling [128]. This finding could explain the exacerbation of the immune response that shapes the pathology and the high cytokine levels characteristic of COVID-19, possibly due to the chemotaxis of neutrophils mediated by IL-8 and IL-6. Finally, it was suggested [129] that the E protein of both SARS-CoV-1 and SARS-CoV-2 has a conserved Bcl-2 Homology 3-like motif, which could inhibit anti-apoptosis proteins, e.g., BCL2, and trigger the apoptosis of T cells. Several compounds are known to disrupt the host-pathogen protein interactome, largely through the inhibition of host proteins. Therefore, this research identifies candidate targets for intervention and suggests that drugs modulating protein-level interactions between virus and host could be relevant to treating COVID-19. By revealing which genes are perturbed during SARS-CoV-2 infection, proteomics-based analyses can thus provide novel insights into host-virus interaction and serve to generate new avenues of investigation for therapeutics.
Viral Virulence
Like that of SARS-CoV-1, the entry of SARS-CoV-2 into host cells is mediated by interactions between the viral spike glycoprotein, S, and human ACE2 (hACE2) [23,26,130,131,132,133,134,135]. Differences in how the S proteins of the two viruses interact with hACE2 could partially account for the increased transmissibility of SARS-CoV-2. Recent studies have reported conflicting binding constants for the S-hACE2 interaction, though they have agreed that the SARS-CoV-2 S protein binds with equal, if not greater, affinity than the SARS-CoV-1 S protein does [9,23,133]. The C-terminal domain of the SARS-CoV-2 S protein in particular was identified as the key region of the virus that interacts with hACE2, and the crystal structure of the C-terminal domain of the SARS-CoV-2 S protein in complex with hACE2 reveals stronger interaction and a higher affinity for receptor binding than that of SARS-CoV-1 [134]. Among the 14 key binding residues identified in the SARS-CoV-1 S protein, eight are conserved in SARS-CoV-2, and the remaining six are semi-conservatively substituted, potentially explaining variation in binding affinity [23,133]. Recent crystal structures have shown that the receptor binding domain (RBD) of the SARS-CoV-2 S protein, like that of other coronaviruses, undergoes stochastic hinge-like movement that flips it from a “closed” conformation, in which key binding residues are hidden at the interface between protomers, to an “open” one [9,23]. Because the RBD plays such a critical role in viral entry, blocking its interaction with ACE2 could represent a promising therapeutic approach. Nevertheless, despite the high structural homology between the SARS-CoV-2 RBD and that of SARS-CoV-1, monoclonal antibodies targeting SARS-CoV-1 RBD failed to bind to SARS-CoV-2-RBD [9]. However, in early research, sera from convalescent SARS patients were found to inhibit SARS-CoV-2 viral entry in vitro , albeit with lower efficiency than it inhibited SARS-CoV-1 [26]. Comparative genomic analysis reveals that several regions of the coronavirus genome are likely critical to virulence. The S1 domain of the spike protein, which contains the receptor binding motif, evolves more rapidly than S ’s S2 domain [16,17]. However, even within the S1 domain, ome regions are more conserved than others, with the receptors in S1’s N-terminal domain (S1-NTD) evolving more rapidly than those in its C-terminal domain (S1-CTD) [17]. Both S1-NTD and S1-CTD are involved in receptor binding and can function as RBDs to bind proteins and sugars [16], but RBDs in the S1-NTD typically bind to sugars, while those in the S1-CTD recognize protein receptors [5]. Viral receptors show higher affinity with protein receptors than sugar receptors [5], which suggests that positive selection on or relaxed conservation of the S1-NTD might reduce the risk of a deleterious mutation that would prevent binding. The SARS-CoV-2 S protein also contains an RRAR furin recognition site at the S1/S2 junction [9,23], setting it apart from both bat coronavirus RaTG13, with which it shares 96% genome sequence identity, and SARS-CoV-1 [136]. Such furin cleavage sites are commonly found in highly virulent influenza viruses, and as such may contribute to the heightened pathogenicity of SARS-CoV-2 [137,138]. The ongoing evolution of the spike protein can be seen from the genomic data. For example, the mutation D614G became dominant by the end of May 2020, soon after its initial appearance in mid-March [139,140], and a variant carrying two mutations (N501Y and 69–70del) that was first observed in the UK in October 2020 [141] has quickly spread around the world [142,143]. Effective cell entry is a critical component to pathogenesis and therefore an important process to understand when examining possible therapeutics. Mechanism of Transmission
Once a human host is infected with a virus, person-to-person viral transmission can occur through several possible mechanisms. The primary mechanisms associated with respiratory viruses are contact, droplet, and aerosol transmission [144]. Contact transmission can occur through either contact with a contagious person or contact with active viral particles on a contaminated surface [145]. This latter mode of transmission is also called fomite transmission [146]. Viral particles can enter the body if they then come in contact with the oral, nasal, eye, or other mucus membranes [145]. Droplet transmission occurs when a contagious individual sneezes, coughs, or exhales and produces respiratory droplets that can contain a large number of viral particles [145]. Contact with these droplets can occur through direct exposure to the droplets, such as breathing in droplets produced by a sneeze [145]. The droplets can also potentially settle on a surface and contribute to fomite transmission [145]. Aerosol transmission refers to much smaller particles (less than 5 micrometers) that are also produced by sneezing, coughing, or exhaling [144,145]. The small size of these particles allows them to remain suspended over a longer period of time and potentially to be moved by air currents [145]. Additionally, viral particles deposited on surfaces via large respiratory droplets can also later be aerosolized [145]. Droplet and/or contact transmission are both well-accepted modes of transmission for many viruses associated with common human illnesses, including influenza and rhinovirus [145]. The extent to which aerosol transmission contributes to the spread of respiratory viruses is less clear. In influenza A, for example, viral particles can be detected in aerosols produced by infected individuals, but the extent to which these particles drive the spread of influenza A infection remains under debate [144,145,147,148,149]. Regardless of its role in the spread of influenza A, however, aerosol transmission likely played a role in outbreaks such as the 1918 Spanish Influenza (H1N1) and 2009 “swine flu” (pH1N1) [149]. Contact, droplet, and aerosol transmission are therefore all worth evaluating when considering possible modes of transmission for a respiratory virus like SARS-CoV-2. ll three of these mechanisms have been identified as possible contributors to the transmission of HCoVs [145], including the highly pathogenic coronaviruses SARS-CoV-1 and MERS-CoV [150,151]. Transmission of SARS-CoV-1 is thought to proceed primarily through droplet transmission, but aerosol transmission is also considered possible [145], and fomite transmission may have also played an important role in some outbreaks [152]. Similarly, the primary mechanism of MERS transmission is thought to be droplets because inter-individual transmission appears to be associated with close interpersonal contact (e.g., household or healthcare settings), but aerosolized particles of the MERS virus have been reported to persist much more robustly than influenza A under a range of environmental conditions [153,154]. While droplet-based and contact transmission were initially put forward as the greatest concern for the spread of SARS-CoV-2 [155], as additional information has emerged, the possibility of aerosol transmission has also been raised [156,157,158]. For example, the detection of SARS-CoV-2 viral particles in air samples taken from hospitals treating COVID-19 patients led to the concern that the virus could be spreading via aerosols [159]. The stability of the virus both in aerosols and on a variety of surfaces appeared similar to that of SARS-CoV-1 [157]. However, while the possibility of aerosol transmission seems plausible, the evidence suggests that droplet transmission is the dominant mechanism driving the spread of the virus [160], and the risk of fomite transmission under real-world conditions is likely to be substantially lower than the conditions used for experimental analyses [161]. These mechanisms may differ in their relevance to different types of transmission events, such as transmission within households, nosocomial transmissions, and transmission in indoor versus outdoor spaces.
Symptoms and Viral Spread
Other aspects of pathogenesis are also important to understanding how the virus spreads, especially the relationship between symptoms, viral shedding, and contagiousness. Symptoms associated with reported cases of COVID-19 range from mild to severe [1], but some individuals who contract COVID-19 remain asymptomatic throughout the duration of the illness [162]. The incubation period, or the time period between exposure and the onset of symptoms, has been estimated at five to eight days, with means of 4.91 (95% confidence interval (CI) 4.35-5.69) and 7.54 (95% CI 6.76-8.56) reported in two different Asian cities and a median of 5 (IQR 1 to 6) reported in a small number of patients in a Beijing hospital [163,164]. However, the exact relationship between contagiousness and viral shedding remains unclear. Estimates suggest that viral shedding can, in some cases, begin as early as 12.3 days (95% CI 5.9-17.0) before the onset of symptoms, although this was found to be very rare, with less than 0.1% of transmission events occurring 7 or more days before symptom onset [165]. Transmissibility appeared to peak around the onset of symptoms (95% CI -0.9 - 0.9 days), and only 44% (95% CI 30–57%) of transmission events were estimated to occur from presymptomatic contacts [165]. As these trends became apparent, concerns arose due to the potential for individuals who did not yet show symptoms to transmit the virus [166]. Recovered individuals may also be able to transmit the virus after their symptoms cease. Estimates of the communicable period based on twenty-four individuals who tested positive for SARS-CoV-2 prior to or without developing symptoms estimated that individuals may be contagious for one to twenty-one days, but they note that this estimate may be low [162]. In an early study, viral nucleic acids were reported to remain at observable levels in the respiratory specimens of recovering hospitalized COVID-19 patients for a median of 20 days and with a maximum observed duration through 37 days, when ata collection for the study ceased [52]. As more estimates of the duration of viral shedding are released, they are beginning to converge around approximately three weeks from first positive PCR test and/or onset of symptoms (which, if present, are usually identified within three days of the initial PCR test). For example, in later studies, viral shedding was reported for up to 28 days following symptom onset [167] and for one to 24 days from first positive PCR test, with a median of 12 days [42]. On the other hand, almost 70% of patients were reported to still have symptoms at the time that viral shedding ceased, although all symptoms reduced in prevalence between onset and cessation of viral shedding [168]. The median time that elapsed between the onset of symptoms and cessation of viral RNA shedding was 23 days and between first positive PCR test and cessation of viral shedding was 17 days [168]. The fact that this study reported symptom onset to predate the first positive PCR test by an average of three days, however, suggests that there may be some methodological differences between it and related studies. Furthermore, an analysis of residents of a nursing home with a known SARS-CoV-2 case measured similar viral load in residents who were asymptomatic regardless of whether they later developed symptoms, and the load in the asymptomatic residents was comparable to that of residents who displayed either typical of atypical symptoms [169]. Taken together, these results suggest that the presence or absence of symptoms are not reliable predictors of viral shedding or of SARS-CoV-2 status (e.g, [170]). However, it should be noted that viral shedding is not necessarily a robust indicator of contagiousness. The risk of spreading the infection was low after ten days from the onset of symptoms, as viral load in sputum was found to be unlikely to pose a significant risk based on efforts to culture samples in vitro [167]. The relationship between symptoms, detectable levels of the virus, and risk of viral spread is therefore complex. The extent to which asymptomatic or presymptomatic individuals are able to transmit SARS-CoV-2 has been a question of high scientific and community interest. Early reports (February and March 2020) described transmission from presymptomatic SARS-CoV-2-positive individuals to close family contacts [171,172]. One of these reports [172] also included a description of an individual who tested positive for SARS-CoV-2 but never developed symptoms. Later analyses also sought to estimate the proportion of infections that could be traced back to a presymptomatic or asymptomatic individual (e.g., [173]). Estimates of the proportion of individuals with asymptomatic infections have varied widely. The proportion of asymptomatic individuals on board the Diamond Princess cruise ship, which was the site of an early COVID-19 outbreak, was estimated at 17.9% [174]. In contrast, a model using the prevalence of antibodies among residents of Wuhan, China estimated a much higher rate of asymptomatic cases, at approximately 7 in 8, or 87.5% [175]. An analysis of the populations of care homes in London found that, among the residents (median age 85), the rate of asymptomatic infection was 43.8%, and among the caretakers (median age 47), the rate was 49.1% [176]. The duration of viral shedding may also be longer in individuals with asymptomatic cases of COVID-19 compared to those who do show symptoms [177]. As a result, the potential for individuals who do not know they have COVID-19 to spread the virus raises significant concerns. In Singapore and Tianjin, two cities studied to estimate incubation period, an estimated 40-50% and 60-80% of cases, respectively, were considered to be caused by contact with asymptomatic individuals [163]. An analysis of viral spread in the Italian town of Vo’, which was the site of an early COVID-19 outbreak, revealed that 42.5% of cases were asymptomatic and that the rate was similar across age groups [178]. The argument was thus made that the town’s lockdown was imperative for controlling the spread of COVID-19 because it isolated asymptomatic individuals. hile more models are likely to emerge to better explore the effect of asymptomatic individuals on SARS-CoV-2 transmission, these results suggest that strategies for identifying and containing asymptomatic but contagious individuals are important for managing community spread.
Estimating the Fatality Rate
Estimating the occurrence of asymptomatic and mild COVID-19 cases is important to identifying the mortality rate associated with COVID-19. The mortality rate of greatest interest would be the total number of fatalities as a fraction of the total number of people infected. One commonly reported metric is the case fatality rate (CFR), which compares the number of COVID-19 related deaths to the number of confirmed or suspected cases. However, in locations without universal testing protocols, it is impossible to identify all infected individuals because so many asymptomatic or mild cases go undetected. Therefore, a more informative metric is the infection fatality rate (IFR), which compares the known deaths to the estimated number of cases. It thus requires the same numerator as CFR, but divides by an approximation of the total number of cases rather than only the observed/suspected cases. IFR varies regionally, with some locations observed to have IFRs as low as 0.17% while others are as high as 1.7% [179]. Estimates of CFR at the national and continental level and IFR at the content level is maintained by the Centre for Evidence-Based Medicine [180]. Several meta-analyses have also sought to estimate IFR at the global scale. These estimates have varied; one peer-reviewed study aggregated data from 24 other studies and estimated IFR at 0.68% (95% CI 0.53%–0.82%), but a preprint that aggregated data from 139 countries calculated a global IFR of 1.04% (95% CI 0.77%-1.38%) when false negatives were considered in the model [179,181]. A similar prevalence estimate was identified through a repeated cross-sectional serosurvey conducted in New York City that estimated the IFR as 0.97% [182]. Examination of serosurvey-based estimates of IFR identified convergence on a global IFR estimate of 0.60% (95% CI 0.42%–0.77%) [179]. All of these studies note that IFR varies widely by location, and it is also expected to vary with demographic and health-related variables such as age, sex, prevalence of comorbidities, and access to healthcare and testing [183]. Estimates of infection rates are becoming more feasible as more data becomes available for modeling and will be bolstered as serological testing becomes more common and more widely available.
Dynamics of Transmission
Disease spread dynamics can be estimated using R , the basic reproduction number, and R t , the effective reproduction number. Accurate estimates of both are crucial to understanding the dynamics of infection and to predicting the effects of different interventions. R is the average number of new (secondary) infections caused by one infected person, assuming a wholly susceptible population [184] and is one of the most important epidemiological parameters [185]. A simple mechanistic model used to describe infectious disease dynamics is a susceptible-infected-recovered compartmental model [186,187]. In this model, individuals move through three states: susceptible, infected, and recovered; two parameters, 𝛾 and 𝛽 , specify the rate at which the infectious recover, and the infection transmission rate, respectively, and R is estimated as the ratio of 𝛽 and 𝛾 [185,188]. A pathogen can invade a susceptible population only if R > 1 [185,189]. The spread of an infectious disease at a particular time t can be uantified by R t , the effective reproduction number, which assumes that part of the population has already recovered (and thus gained immunity to reinfection) or that mitigating interventions have been put into place. For example, if only a fraction S t of the population is still susceptible, R t = S t x R . When R t is greater than 1, an epidemic grows (i.e., the proportion of the population that is infectious increases); when R t is less than 1, the proportion of the population that is infectious decreases. R and R t can be estimated directly from epidemiological data or inferred using susceptible-infected-recovered-type models. To accurately capture the dynamics of SARS-CoV-2, the addition of a fourth compartment, i.e. a susceptible-exposed-infectious-recovered model may be appropriate. Estimates of R for COVID-19 lie in the range R =1.4-6.5 [190,191,192]. Variation in R is expected between different populations, and the estimated values of R discussed below are for specific populations in specific environments. The different estimates of R should not necessarily be interpreted as a range of estimates of the same underlying parameter. In one study of international cases, the predicted value was R =1.7 [193]. In China (both Hubei province and nationwide), the value was predicted to lie in the range R =2.0-3.6 [190,194,195]. Another estimate based on a cruise ship where an outbreak occurred predicted R =2.28 [196]. Susceptible-exposed-infectious-recovered model-derived estimates of R range from 2.0 - 6.5 in China [197,198,199,200] to R =4.8 in France [201]. Using the same model as for the French population, a study estimated R =2.6 in South Korea [201], which is consistent with other studies [202]. From a meta-analysis of studies estimating R , [191] the median R was estimated to be 2.79 (IQR 1.16) based on twelve studies published between January 1 and February 7, 2020. Inference of the effective reproduction number can provide insight into how populations respond to an infection and the effectiveness of interventions. In China, R t was predicted to lie in the range 1.6-2.6 in January 2020, before travel restrictions [203]. R t decreased from 2.35 one week before travel restrictions were imposed (January 23, 2020), to 1.05 one week after. Using their model, the authors also estimated the probability of new outbreaks occurring. Assuming individual-level variation in transmission comparable to that of MERS or SARS, the probability of a single individual exporting the virus and causing a large outbreak is 17-25%, and assuming variation like that of SARS and transmission patterns like those observed for COVID-19 in Wuhan, the probability of a large outbreak occurring after ≥4 infections exist at a new location is greater than 50%. An independent study came to similar conclusions, finding R t =2.38 in the two-week period before January 23 with a decrease to R t = 1.34 (using data from January 24 to February 3) or R t =0.98 (using data from January 24 to February 8) [192]. In South Korea, R t was inferred for February through March 2020 in two cities, Daegu (the center of the outbreak) and Seoul [202]. Metro data was also analyzed to estimate the effects of social distancing measures. R t decreased in Daegu from around 3 to <1 over the period that social distancing measures were introduced. In Seoul, R t decreased slightly, but remained close to 1 (and larger than R t in Daegu). These findings indicate that social distancing measures appeared to be effective in containing the infection in Daegu, but in Seoul, R t remained above 1, meaning secondary outbreaks remained possible. The study also shows the importance of region-specific analysis: the large decline in case load nationwide was mainly due to the Daegu region and could mask persistence of the epidemic in other regions, such as Seoul and Gyeonggi-do. In Iran, estimates of R t declined from 4.86 in the first week to 2.1 by the fourth week after the irst cases were reported [204]. In Europe, analysis of 11 countries inferred the dynamics of R t over a time range from the beginning of the outbreak until March 28, 2020, by which point most countries had implemented major interventions (such as stay-at-home orders, public gathering bans, and school closures) [205]. Across all countries, the mean R t before interventions began was estimated as 3.87; R t varied considerably, from below 3 in Norway to above 4.5 in Spain. After interventions, R t decreased by an average of 64% across all countries, with mean R t =1.43. The lowest predicted value was 0.97 for Norway and the highest was 2.64 for Sweden, which could be related to the fact that Sweden did not implement social distancing measures on the same scale as other countries. The study concludes that while large changes in R t are observed, it is too early to tell whether the interventions put into place are sufficient to decrease R t below 1. More generally, population-level epidemic dynamics can be both observed and modeled [188]. Data and empirically determined biological mechanisms inform models, while models can be used to try to understand data and systems of interest or to make predictions about possible future dynamics, such as the estimation of capacity needs [206] or the comparison of predicted outcomes among prevention and control strategies [207,208]. Many current efforts to model R t have also led to tools that assist the visualization of estimates in real time or over recent intervals [209,210]. These are valuable resources, yet it is also important to note that the estimates arise from models containing many assumptions and are dependent on the quality of the data they use, which varies widely by region. Molecular Signatures and Transmission
Genetic variation in SARS-CoV-2 has been used to elucidate patterns over time and space. Mutations observed in individual SARS-CoV-2 genome sequences can be used to trace transmission patterns and have provided insights during outbreak investigations [211,212,213]. Similar mutations observed in several patients may indicate that the patients belong to the same transmission group. The tracking of SARS-CoV-2 mutations is recognized as an essential tool for controlling future outbreaks and tracing the path of the spread of SARS-CoV-2. Efforts vary widely by country: the UK has coordinated has coordinated a national database of viral genomes [214]; no such coordination has been achieved in the USA. Several studies used phylogenetic analysis to determine the source of local COVID-19 outbreaks in Connecticut (USA), [215], the New York City area (USA) [216], and Iceland [217]. There is an ongoing effort to collect SARS-CoV-2 genomes throughout the COVID-19 outbreak, and as of January 18, 2021 more than 381,000 genome sequences have been collected from patients. The sequencing data can be found at GISAID [218], NCBI [219], and COVID-19 data portal [220].
Conclusions
The novel coronavirus SARS-CoV-2 is the third HCoV to emerge in the 21st century, and research into previous HCoVs has provided a strong foundation for characterizing the pathogenesis and transmission of SARS-CoV-2. Critical insights into how the virus interacts with human cells have been gained from previous research into HCoVs and other viral infections. As with other HCoVs, the immune response to SARS-CoV-2 is likely driven by detection of its spike protein, which allows it to enter cells through ACE2. Epithelial cells have also emerged as the ajor cellular target of the virus, contextualizing the respiratory and gastrointestinal symptoms that are frequently observed in COVID-19. Many of the mechanisms that facilitate the pathogenesis of SARS-CoV-2 are currently under consideration as possible targets for the treatment or prevention of COVID-19. Research in other viruses also provides a foundation for understanding the transmission of SARS-CoV-2 among people and can therefore inform efforts to control the virus’s spread. The extent to which aerosol and fomite transmission contribute to the spread of SARS-CoV-2 remains a question: in general, much like SARS-CoV-1 and MERS-CoV, this virus seems to be spread primarily by droplet transmission. Asymptomatic transmission was also a concern in the SARS outbreak of 2002-03 and, as in current pandemic, presented challenges for estimating rates of infection [221]. However, in the current pandemic, we have been fortunate to be able to build on top of 18 years of SARS-CoV-1 research in order to rapidly ascertain the identity and behavior of the virus. Even with the background obtained from research in SARS and MERS, COVID-19 has revealed itself to be a complex and difficult-to-characterize disease that has many possible presentations that vary with age. Variability in presentation, including cases with no respiratory symptoms or with no symptoms altogether, were also reported during the SARS epidemic at the beginning of the 21st century [221]. The variability of both which symptoms present and their severity have presented challenges for public health agencies seeking to provide clear recommendations regarding which symptoms indicate SARS-CoV-2 infection and should prompt isolation. Asymptomatic cases add complexity both to efforts to estimate statistics such as R and R t , which are critical to understanding the transmission of the virus, and IFR, which is an important component of understanding its impact on a given population. The development of diagnostic technologies over the course of the pandemic has facilitated more accurate identification, including of asymptomatic cases. As more cases have been diagnosed, the health conditions and patient characteristics associated with more severe infection have also become more clear, although there are likely to be significant sociocultural elements that also influence these outcomes. While many efforts have focused on adults, and especially older adults because of the susceptibility of this demographic, additional research is needed to understand the presentation of COVID-19 and MIS-C in pediatric patients. As more information is uncovered about the pathogenesis of HCoV and SARS-CoV-2 specifically, the diverse symptomatology of COVID-19 has and likely will continue to conform with the ever-broadening understanding of how SARS-CoV-2 functions within a human host. While the SARS-CoV-2 virus is very similar to other HCoV in several ways, including in its genomic structure and the structure of the virus itself, there are also some differences that may account for differences in the COVID-19 pandemic compared to the SARS and MERS epidemics of the past two decades. The R of SARS-CoV-2 has been estimated to be similar to SARS-CoV-1 but much higher than that of MERS-CoV [222,222]. While the structures of the viruses are very similar, evolution among these species may account for differences in their transmissibility and virulence. For example, the acquisition of a furin cleavage site the S1/S2 boundary within the SARS-CoV-2 S protein may be associated with increased virulence. Additionally, concerns have been raised about the accumulation of mutations within the SARS-CoV-2 species itself, and whether these could influence virulence. The coming of age of genomic technologies has made these types of analyses feasible, and genomics research characterizing changes in SARS-CoV-2 along with temporal and spatial movement is likely to rovide additional insights into whether within-species evolution influences the effect of the virus on the human host. Additionally, the rapid development of sequencing technologies over the past decade has made it possible to rapidly characterize the host response to the virus. For example, proteomics analysis of patient-derived cells revealed candidate genes whose regulation is altered by SARS-CoV-2 infection, suggesting possible approaches for pharmaceutical invention and providing insight into which systems are likely to be disrupted in COVID-19 [127]. As more patient data becomes available, the biotechnological advances of the 2000s are expected to allow for more rapid identification of potential drug targets than was feasible during the SARS, or even MERS, pandemic. Thus, though the COVID-19 crisis is still evolving, the insights acquired over the past 20 years of HCoV research have provided a solid foundation for understanding the SARS-CoV-2 virus and the disease it causes. As the scientific community continues to respond to COVID-19 and to elucidate more of the relationships between viral pathogenesis, transmission, and symptomatology, and as more data about the regulatory shifts associated with COVID-19 become available, this understanding will no doubt continue to evolve and to reveal additional connections among virology, pathogenesis, and health. As additional information becomes available, this review will be updated to reflect the changing state of research in this area. At present, understanding the SARS-CoV-2 virus and its pathogenesis is critical to a holistic understanding of the COVID-19 pandemic. Additional Items
Competing Interests
Author Competing Interests Last Reviewed
Halie M. Rando None 2021-01-20 Adam L. MacLean None 2020-11-11 Alexandra J. Lee None 2020-11-09 Sandipan Ray None 2020-11-11 Vikas Bansal None 2021-01-25 Ashwin N. Skelly None 2020-11-11 Elizabeth Sell None 2020-11-11 John J. Dziak None 2020-11-11 Lamonica Shinholster None 2020-11-11 Lucy D'Agostino McGowan Received consulting fees from Acelity and Sanofi in the past five years 2020-11-10 Marouen Ben Guebila None 2020-11-11 Nils Wellhausen None 2020-11-03 Sergey Knyazev None 2020-11-11 imina M. Boca None 2020-11-07 Stephen Capone None 2020-11-11 Yanjun Qi None 2020-07-09 YoSon Park Now employed by Pfizer (subsequent to contributions to this project) 2020-01-22 Yuchen Sun None 2020-11-11 David Mai None 2021-01-08 Christian Brueffer Employee and shareholder of SAGA Diagnostics AB. 2020-11-11 James Brian Byrd Funded by FastGrants to conduct a COVID-19-related clinical trial 2020-11-12 Jinhui Wang None 2021-01-21 Ronan Lordan None 2020-11-03 Ryan Velazquez None 2020-11-10 Gregory L Szeto None 2020-11-16 John P. Barton None 2020-11-11 Rishi Raj Goel None 2021-01-20 Serghei Mangul None 2020-11-11 Tiago Lubiana None 2020-11-11 COVID-19 Review Consortium None 2021-01-16 Anthony Gitter Filed a patent application with the Wisconsin Alumni Research Foundation related to classifying activated T cells 2020-11-10 Casey S. Greene None 2021-01-20
Author Contributions
Author Contributions
Halie M. Rando Project Administration, Writing - Original Draft, Writing - Review & Editing Adam L. MacLean Writing - Original Draft, Writing - Review & Editing Alexandra J. Lee Writing - Original Draft, Writing - Review & Editing Sandipan Ray Writing - Original Draft, Writing - Review & Editing Vikas Bansal Writing - Original Draft, Writing - Review & Editing Ashwin N. Skelly Writing - Original Draft, Writing - Review & Editing Elizabeth Sell Writing - Original Draft, Writing - Review & Editing John J. Dziak Writing - Original Draft, Writing - Review & Editing Lamonica Shinholster Writing - Original Draft Lucy D'Agostino McGowan Writing - Original Draft, Writing - Review & Editing Marouen Ben Guebila Writing - Original Draft, Writing - Review & Editing Nils Wellhausen Visualization, Writing - Original Draft, Writing - Review & Editing ergey Knyazev Writing - Original Draft, Writing - Review & Editing Simina M. Boca Writing - Review & Editing Stephen Capone Writing - Original Draft, Writing - Review & Editing Yanjun Qi Visualization YoSon Park Writing - Original Draft, Writing - Review & Editing Yuchen Sun Visualization David Mai Writing - Original Draft, Writing - Review & Editing Christian Brueffer Writing - Original Draft, Writing - Review & Editing James Brian Byrd Writing - Original Draft, Writing - Review & Editing Jinhui Wang Writing - Review & Editing Ronan Lordan Writing - Review & Editing Ryan Velazquez Writing - Review & Editing Gregory L Szeto Writing - Review & Editing John P. Barton Writing - Original Draft, Writing - Review & Editing Rishi Raj Goel Writing - Original Draft, Writing - Review & Editing Serghei Mangul Writing - Review & Editing Tiago Lubiana Writing - Review & Editing COVID-19 Review Consortium Project Administration Anthony Gitter Methodology, Project Administration, Software, Writing - Review & Editing Casey S. Greene Conceptualization, Software, Writing - Review & Editing
Acknowledgements
We thank Nick DeVito for assistance with the Evidence-Based Medicine Data Lab COVID-19 TrialsTracker data and Vincent Rubinetti and Daniel Himmelstein for feedback on and support with Manubot. We thank Yael Evelyn Marshall who contributed writing (original draft) as well as reviewing and editing of pieces of the text but who did not formally approve the manuscript, as well as Ronnie Russell, who contributed text to and helped develop the structure of the manuscript early in the writing process and Matthias Fax who helped with writing and editing text related to diagnostics. We are grateful to the following contributors for reviewing pieces of the text: Nadia Danilova, James Eberwine and Ipsita Krishnan.
References Coronavirus Disease 2019 (COVID-19) – Symptoms
CDC
Centers for Disease Control and Prevention
WHO Declares COVID-19 a Pandemic
Domenico Cucinotta, Maurizio Vanelli
Acta Bio Medica Atenei Parmensis (2020-03-19) https://doi.org/ggq86h DOI: 10.23750/abm.v91i1.9397 · PMID: 32191675 · PMCID: PMC7569573 3.
Acute lung injury in patients with COVID -
19 infection
Liyang Li, Qihong Huang, Diane C. Wang, David H. Ingbar, Xiangdong Wang
Clinical and Translational Medicine (2020-03-31) https://doi.org/ghqcrz DOI: 10.1002/ctm2.16 · PMID: 32508022 · PMCID: PMC7240840 4.
A Novel Coronavirus Genome Identified in a Cluster of Pneumonia Cases — Wuhan, China 2019−2020
Wenjie Tan, Xiang Zhao, Xuejun Ma, Wenling Wang, Peihua Niu, Wenbo Xu, George F. Gao, Guizhen Wu, MHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Beijing, China
China CDC Weekly (2020) https://doi.org/gg8z47 DOI: 10.46234/ccdcw2020.017 5.
Structure, Function, and Evolution of Coronavirus Spike Proteins
Fang Li
Annual Review of Virology (2016-09-29) https://doi.org/ggr7gv DOI: 10.1146/annurev-virology-110615-042301 · PMID: 27578435 · PMCID: PMC5457962 6.
A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster
Jasper Fuk-Woo Chan, Shuofeng Yuan, Kin-Hang Kok, Kelvin Kai-Wang To, Hin Chu, Jin Yang, Fanfan Xing, Jieling Liu, Cyril Chik-Yan Yip, Rosana Wing-Shan Poon, … Kwok-Yung Yuen
The Lancet (2020-02) https://doi.org/ggjs7j DOI: 10.1016/s0140-6736(20)30154-9 · PMID: 31986261 · PMCID: PMC7159286 7.
Fields virology
Bernard N. Fields, David M. Knipe, Peter M. Howley (editors)
Wolters Kluwer Health/Lippincott Williams & Wilkins (2007) ISBN: 9780781760607 8.
Important Role for the Transmembrane Domain of Severe Acute Respiratory Syndrome Coronavirus Spike Protein during Entry
Rene Broer, Bertrand Boson, Willy Spaan, François-Loïc Cosset, Jeroen Corver
Journal of Virology (2006-02-01) https://doi.org/dvvg2h DOI: 10.1128/jvi.80.3.1302-1310.2006 · PMID: 16415007 · PMCID: PMC1346921 9.
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Daniel Wrapp, Nianshuang Wang, Kizzmekia S. Corbett, Jory A. Goldsmith, Ching-Lin Hsieh, Olubukola Abiona, Barney S. Graham, Jason S. McLellan
Science (2020-03-13) https://doi.org/ggmtk2 DOI: 10.1126/science.abb2507 · PMID: 32075877 0.
Medical microbiology
Samuel Baron (editor)
University of Texas Medical Branch at Galveston (1996) ISBN: 9780963117212 11.
Coronaviruses: An Overview of Their Replication and Pathogenesis
Anthony R. Fehr, Stanley Perlman
Methods in Molecular Biology (2015) https://doi.org/ggpc6n DOI: 10.1007/978-1-4939-2438-7_1 · PMID: 25720466 · PMCID: PMC4369385 12.
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
Roujian Lu, Xiang Zhao, Juan Li, Peihua Niu, Bo Yang, Honglong Wu, Wenling Wang, Hao Song, Baoying Huang, Na Zhu, … Wenjie Tan
The Lancet (2020-02) https://doi.org/ggjr43 DOI: 10.1016/s0140-6736(20)30251-8 13.
Emerging coronaviruses: Genome structure, replication, and pathogenesis
Yu Chen, Qianyun Liu, Deyin Guo
Journal of Medical Virology (2020-02-07) https://doi.org/ggjvwj DOI: 10.1002/jmv.25681 · PMID: 31967327 14.
SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway
Hongliang Wang, Peng Yang, Kangtai Liu, Feng Guo, Yanli Zhang, Gongyi Zhang, Chengyu Jiang
Cell Research (2008-01-29) https://doi.org/bp9275 DOI: 10.1038/cr.2008.15 · PMID: 18227861 · PMCID: PMC7091891 15.
Virus Entry by Endocytosis
Jason Mercer, Mario Schelhaas, Ari Helenius
Annual Review of Biochemistry (2010-06-07) https://doi.org/cw4dnb DOI: 10.1146/annurev-biochem-060208-104626 · PMID: 20196649 16.
Mechanisms of Coronavirus Cell Entry Mediated by the Viral Spike Protein
Sandrine Belouzard, Jean K. Millet, Beth N. Licitra, Gary R. Whittaker
Viruses (2012-06-20) https://doi.org/gbbktb DOI: 10.3390/v4061011 · PMID: 22816037 · PMCID: PMC3397359 17.
Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop
Javier A. Jaimes, Nicole M. André, Joshua S. Chappie, Jean K. Millet, Gary R. Whittaker
Journal of Molecular Biology (2020-05) https://doi.org/ggtxhr DOI: 10.1016/j.jmb.2020.04.009 · PMID: 32320687 · PMCID: PMC7166309 18.
Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target aibo Zhang, Josef M. Penninger, Yimin Li, Nanshan Zhong, Arthur S. Slutsky
Intensive Care Medicine (2020-03-03) https://doi.org/ggpx6p DOI: 10.1007/s00134-020-05985-9 · PMID: 32125455 · PMCID: PMC7079879 19.
Infection of Human Airway Epithelia by Sars Coronavirus is Associated with ACE2 Expression and Localization
Hong Peng Jia, Dwight C. Look, Melissa Hickey, Lei Shi, Lecia Pewe, Jason Netland, Michael Farzan, Christine Wohlford-Lenane, Stanley Perlman, Paul B. McCray
Advances in Experimental Medicine and Biology (2006) https://doi.org/dhh5tp DOI: 10.1007/978-0-387-33012-9_85 · PMID: 17037581 · PMCID: PMC7123641 20.
The protein expression profile of ACE2 in human tissues
Feria Hikmet, Loren Méar, Åsa Edvinsson, Patrick Micke, Mathias Uhlén, Cecilia Lindskog
Molecular Systems Biology (2020-07-26) https://doi.org/gg6mxv DOI: 10.15252/msb.20209610 · PMID: 32715618 · PMCID: PMC7383091 21.
Receptor Recognition Mechanisms of Coronaviruses: a Decade of Structural Studies
Fang Li
Journal of Virology (2015-02-15) https://doi.org/f633jb DOI: 10.1128/jvi.02615-14 · PMID: 25428871 · PMCID: PMC4338876 22.
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Lanying Du, Yuxian He, Yusen Zhou, Shuwen Liu, Bo-Jian Zheng, Shibo Jiang
Nature Reviews Microbiology (2009-02-09) https://doi.org/d4tq4t DOI: 10.1038/nrmicro2090 · PMID: 19198616 · PMCID: PMC2750777 23.
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
Alexandra C. Walls, Young-Jun Park, M. Alejandra Tortorici, Abigail Wall, Andrew T. McGuire, David Veesler
Cell (2020-04) https://doi.org/dpvh DOI: 10.1016/j.cell.2020.02.058 · PMID: 32155444 · PMCID: PMC7102599 24.
Molecular Interactions in the Assembly of Coronaviruses
Cornelis A. M. de Haan, Peter J. M. Rottier
Advances in Virus Research (2005) https://doi.org/cf8chz DOI: 10.1016/s0065-3527(05)64006-7 · PMID: 16139595 · PMCID: PMC7112327 25.
Coronavirus membrane fusion mechanism offers a potential target for antiviral development
Tiffany Tang, Miya Bidon, Javier A. Jaimes, Gary R. Whittaker, Susan Daniel
Antiviral Research (2020-06) https://doi.org/ggr23b DOI: 10.1016/j.antiviral.2020.104792 · PMID: 32272173 · PMCID: PMC7194977 26.
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann, Hannah Kleine-Weber, Simon Schroeder, Nadine Krüger, Tanja Herrler, Sandra Erichsen, Tobias S. Schiergens, Georg Herrler, Nai-Huei Wu, Andreas Nitsche, … tefan Pöhlmann
Cell (2020-04) https://doi.org/ggnq74 DOI: 10.1016/j.cell.2020.02.052 · PMID: 32142651 · PMCID: PMC7102627 27.
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
Xiuyuan Ou, Yan Liu, Xiaobo Lei, Pei Li, Dan Mi, Lili Ren, Li Guo, Ruixuan Guo, Ting Chen, Jiaxin Hu, … Zhaohui Qian
Nature Communications (2020-03-27) https://doi.org/ggqsrf DOI: 10.1038/s41467-020-15562-9 · PMID: 32221306 · PMCID: PMC7100515 28.
Coronaviridae ~ ViralZone page https://viralzone.expasy.org/30?outline 29.
Spatiotemporal interplay of severe acute respiratory syndrome coronavirus and respiratory mucosal cells drives viral dissemination in rhesus macaques
L Liu, Q Wei, K Nishiura, J Peng, H Wang, C Midkiff, X Alvarez, C Qin, A Lackner, Z Chen
Mucosal Immunology (2015-12-09) https://doi.org/f8r7dk DOI: 10.1038/mi.2015.127 · PMID: 26647718 · PMCID: PMC4900951 30.
Understanding Viral dsRNA-Mediated Innate Immune Responses at the Cellular Level Using a Rainbow Trout Model
Sarah J. Poynter, Stephanie J. DeWitte-Orr
Frontiers in Immunology (2018-04-23) https://doi.org/gdhpbs DOI: 10.3389/fimmu.2018.00829 · PMID: 29740439 · PMCID: PMC5924774 31.
Ultrastructure and Origin of Membrane Vesicles Associated with the Severe Acute Respiratory Syndrome Coronavirus Replication Complex
Eric J. Snijder, Yvonne van der Meer, Jessika Zevenhoven-Dobbe, Jos J. M. Onderwater, Jannes van der Meulen, Henk K. Koerten, A. Mieke Mommaas
Journal of Virology (2006-06-15) https://doi.org/b2rh4r DOI: 10.1128/jvi.02501-05 · PMID: 16731931 · PMCID: PMC1472606 32.
Molecular immune pathogenesis and diagnosis of COVID-19
Xiaowei Li, Manman Geng, Yizhao Peng, Liesu Meng, Shemin Lu
Journal of Pharmaceutical Analysis (2020-04) https://doi.org/ggppqg DOI: 10.1016/j.jpha.2020.03.001 · PMID: 32282863 · PMCID: PMC7104082 33.
Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2
Matthias Thoms, Robert Buschauer, Michael Ameismeier, Lennart Koepke, Timo Denk, Maximilian Hirschenberger, Hanna Kratzat, Manuel Hayn, Timur Mackens-Kiani, Jingdong Cheng, … Roland Beckmann
Science (2020-09-04) https://doi.org/gg69nq DOI: 10.1126/science.abc8665 · PMID: 32680882 · PMCID: PMC7402621 34.
Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic sian Pacific Journal of Allergy and Immunology (2020) https://doi.org/ggpvxw DOI: 10.12932/ap-200220-0772 · PMID: 32105090 35.
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Wenhui Li, Michael J. Moore, Natalya Vasilieva, Jianhua Sui, Swee Kee Wong, Michael A. Berne, Mohan Somasundaran, John L. Sullivan, Katherine Luzuriaga, Thomas C. Greenough, … Michael Farzan
Nature (2003-11) https://doi.org/bqvpjh DOI: 10.1038/nature02145 · PMID: 14647384 · PMCID: PMC7095016 36.
Efficient Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein by the Transmembrane Protease TMPRSS2
Shutoku Matsuyama, Noriyo Nagata, Kazuya Shirato, Miyuki Kawase, Makoto Takeda, Fumihiro Taguchi
Journal of Virology (2010-12-15) https://doi.org/d4hnfr DOI: 10.1128/jvi.01542-10 · PMID: 20926566 · PMCID: PMC3004351 37.
Evidence that TMPRSS2 Activates the Severe Acute Respiratory Syndrome Coronavirus Spike Protein for Membrane Fusion and Reduces Viral Control by the Humoral Immune Response
I. Glowacka, S. Bertram, M. A. Muller, P. Allen, E. Soilleux, S. Pfefferle, I. Steffen, T. S. Tsegaye, Y. He, K. Gnirss, … S. Pohlmann
Journal of Virology (2011-02-16) https://doi.org/bg97wb DOI: 10.1128/jvi.02232-10 · PMID: 21325420 · PMCID: PMC3126222 38.
Increasing Host Cellular Receptor—Angiotensin-Converting Enzyme 2 (ACE2) Expression by Coronavirus may Facilitate 2019-nCoV Infection
Pei-Hui Wang, Yun Cheng
Cold Spring Harbor Laboratory (2020-02-27) https://doi.org/ggscwd DOI: 10.1101/2020.02.24.963348 39.
Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor
Yanwei Li, Wei Zhou, Li Yang, Ran You
Pharmacological Research (2020-07) https://doi.org/ggtxhs DOI: 10.1016/j.phrs.2020.104833 · PMID: 32302706 · PMCID: PMC7194807 40.
Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis
I Hamming, W Timens, MLC Bulthuis, AT Lely, GJ Navis, H van Goor
The Journal of Pathology (2004-06) https://doi.org/bhpzc3 DOI: 10.1002/path.1570 · PMID: 15141377 41.
Detection of SARS-CoV-2 in Different Types of Clinical Specimens
Wenling Wang, Yanli Xu, Ruqin Gao, Roujian Lu, Kai Han, Guizhen Wu, Wenjie Tan
JAMA (2020-03-11) https://doi.org/ggpp6h DOI: 10.1001/jama.2020.3786 · PMID: 32159775 · PMCID: PMC7066521 2.
Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore
Barnaby Edward Young, Sean Wei Xiang Ong, Shirin Kalimuddin, Jenny G. Low, Seow Yen Tan, Jiashen Loh, Oon-Tek Ng, Kalisvar Marimuthu, Li Wei Ang, Tze Minn Mak, … for the Singapore 2019 Novel Coronavirus Outbreak Research Team
JAMA (2020-04-21) https://doi.org/ggnb37 DOI: 10.1001/jama.2020.3204 · PMID: 32125362 · PMCID: PMC7054855 43.
Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients
Yun Ling, Shui-Bao Xu, Yi-Xiao Lin, Di Tian, Zhao-Qin Zhu, Fa-Hui Dai, Fan Wu, Zhi-Gang Song, Wei Huang, Jun Chen, … Hong-Zhou Lu
Chinese Medical Journal (2020-05-05) https://doi.org/ggnnz8 DOI: 10.1097/cm9.0000000000000774 · PMID: 32118639 · PMCID: PMC7147278 44.
Postmortem examination of COVID -
19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction
Thomas Menter, Jasmin D Haslbauer, Ronny Nienhold, Spasenija Savic, Helmut Hopfer, Nikolaus Deigendesch, Stephan Frank, Daniel Turek, Niels Willi, Hans Pargger, … Alexandar Tzankov
Histopathology (2020-07-05) https://doi.org/ggwr32 DOI: 10.1111/his.14134 · PMID: 32364264 · PMCID: PMC7496150 45.
Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China
Shaobo Shi, Mu Qin, Bo Shen, Yuli Cai, Tao Liu, Fan Yang, Wei Gong, Xu Liu, Jinjun Liang, Qinyan Zhao, … Congxin Huang
JAMA Cardiology (2020-07-01) https://doi.org/ggq8qf DOI: 10.1001/jamacardio.2020.0950 · PMID: 32211816 · PMCID: PMC7097841 46.
The need for urogenital tract monitoring in COVID-19
Shangqian Wang, Xiang Zhou, Tongtong Zhang, Zengjun Wang
Nature Reviews Urology (2020-04-20) https://doi.org/ggv4xb DOI: 10.1038/s41585-020-0319-7 · PMID: 32313110 · PMCID: PMC7186932 47.
Acute kidney injury in SARS-CoV-2 infected patients
Vito Fanelli, Marco Fiorentino, Vincenzo Cantaluppi, Loreto Gesualdo, Giovanni Stallone, Claudio Ronco, Giuseppe Castellano
Critical Care (2020-04-16) https://doi.org/ggv45f DOI: 10.1186/s13054-020-02872-z · PMID: 32299479 · PMCID: PMC7161433 48.
Liver injury in COVID-19: management and challenges
Chao Zhang, Lei Shi, Fu-Sheng Wang
The Lancet Gastroenterology & Hepatology (2020-05) https://doi.org/ggpx6s DOI: 10.1016/s2468-1253(20)30057-1 · PMID: 32145190 · PMCID: PMC7129165 9.
Evidence for Gastrointestinal Infection of SARS-CoV-2
Fei Xiao, Meiwen Tang, Xiaobin Zheng, Ye Liu, Xiaofeng Li, Hong Shan
Gastroenterology (2020-05) https://doi.org/ggpx27 DOI: 10.1053/j.gastro.2020.02.055 · PMID: 32142773 · PMCID: PMC7130181 50.
Qin Yan Gao, Ying Xuan Chen, Jing Yuan Fang
Journal of Digestive Diseases (2020-03) https://doi.org/ggqr86 DOI: 10.1111/1751-2980.12851 · PMID: 32096611 · PMCID: PMC7162053 51.
Clinical Characteristics of Coronavirus Disease 2019 in China
Wei-jie Guan, Zheng-yi Ni, Yu Hu, Wen-hua Liang, Chun-quan Ou, Jian-xing He, Lei Liu, Hong Shan, Chun-liang Lei, David S. C. Hui, … Nan-shan Zhong
New England Journal of Medicine (2020-04-30) https://doi.org/ggm6dh DOI: 10.1056/nejmoa2002032 · PMID: 32109013 · PMCID: PMC7092819 52.
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
Fei Zhou, Ting Yu, Ronghui Du, Guohui Fan, Ying Liu, Zhibo Liu, Jie Xiang, Yeming Wang, Bin Song, Xiaoying Gu, … Bin Cao
The Lancet (2020-03) https://doi.org/ggnxb3 DOI: 10.1016/s0140-6736(20)30566-3 53.
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area
Safiya Richardson, Jamie S. Hirsch, Mangala Narasimhan, James M. Crawford, Thomas McGinn, Karina W. Davidson, Douglas P. Barnaby, Lance B. Becker, John D. Chelico, Stuart L. Cohen, … and the Northwell COVID-19 Research Consortium
JAMA (2020-05-26) https://doi.org/ggsrkd DOI: 10.1001/jama.2020.6775 · PMID: 32320003 · PMCID: PMC7177629 54.
Clinical Characteristics of Covid-19 in New York City
Parag Goyal, Justin J. Choi, Laura C. Pinheiro, Edward J. Schenck, Ruijun Chen, Assem Jabri, Michael J. Satlin, Thomas R. Campion, Musarrat Nahid, Joanna B. Ringel, … Monika M. Safford
New England Journal of Medicine (2020-06-11) https://doi.org/ggtsjc DOI: 10.1056/nejmc2010419 · PMID: 32302078 · PMCID: PMC7182018 55.
Symptom Profiles of a Convenience Sample of Patients with COVID-19 — United States, January–April 2020
Rachel M. Burke, Marie E. Killerby, Suzanne Newton, Candace E. Ashworth, Abby L. Berns, Skyler Brennan, Jonathan M. Bressler, Erica Bye, Richard Crawford, Laurel Harduar Morano, … Case Investigation Form Working Group
MMWR. Morbidity and Mortality Weekly Report (2020-07-17) https://doi.org/gg8r2m DOI: 10.15585/mmwr.mm6928a2 · PMID: 32673296 · PMCID: PMC7366851 56.
Population-scale Longitudinal Mapping of COVID-19 Symptoms, Behavior, and Testing Identifies Contributors to Continued Disease Spread in the United States illiam E. Allen, Han Altae-Tran, James Briggs, Xin Jin, Glen McGee, Andy Shi, Rumya Raghavan, Mireille Kamariza, Nicole Nova, Albert Pereta, … Xihong Lin
Cold Spring Harbor Laboratory (2020-06-11) https://doi.org/gg8skn DOI: 10.1101/2020.06.09.20126813 · PMID: 32577674 · PMCID: PMC7302230 57.
Extrapulmonary manifestations of COVID-19
Aakriti Gupta, Mahesh V. Madhavan, Kartik Sehgal, Nandini Nair, Shiwani Mahajan, Tejasav S. Sehrawat, Behnood Bikdeli, Neha Ahluwalia, John C. Ausiello, Elaine Y. Wan, … Donald W. Landry
Nature Medicine (2020-07-10) https://doi.org/gg4r37 DOI: 10.1038/s41591-020-0968-3 · PMID: 32651579 58.
Acute kidney injury in patients hospitalized with COVID-19
Jamie S. Hirsch, Jia H. Ng, Daniel W. Ross, Purva Sharma, Hitesh H. Shah, Richard L. Barnett, Azzour D. Hazzan, Steven Fishbane, Kenar D. Jhaveri, Mersema Abate, … Jia Hwei. Ng
Kidney International (2020-07) https://doi.org/ggx24k DOI: 10.1016/j.kint.2020.05.006 · PMID: 32416116 · PMCID: PMC7229463 59.
Nervous system involvement after infection with COVID-19 and other coronaviruses
Yeshun Wu, Xiaolin Xu, Zijun Chen, Jiahao Duan, Kenji Hashimoto, Ling Yang, Cunming Liu, Chun Yang
Brain, Behavior, and Immunity (2020-07) https://doi.org/ggq7s2 DOI: 10.1016/j.bbi.2020.03.031 · PMID: 32240762 · PMCID: PMC7146689 60.
Neurological associations of COVID-19
Mark A Ellul, Laura Benjamin, Bhagteshwar Singh, Suzannah Lant, Benedict Daniel Michael, Ava Easton, Rachel Kneen, Sylviane Defres, Jim Sejvar, Tom Solomon
The Lancet Neurology (2020-09) https://doi.org/d259 DOI: 10.1016/s1474-4422(20)30221-0 · PMID: 32622375 · PMCID: PMC7332267 61.
Update on the neurology of COVID - Josef Finsterer, Claudia Stollberger
Journal of Medical Virology (2020-06-02) https://doi.org/gg2qnn DOI: 10.1002/jmv.26000 · PMID: 32401352 · PMCID: PMC7272942 62. -
19: A Global Threat to the Nervous System
Igor J. Koralnik, Kenneth L. Tyler
Annals of Neurology (2020-06-23) https://doi.org/gg3hzh DOI: 10.1002/ana.25807 · PMID: 32506549 · PMCID: PMC7300753 63.
Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19
Jenny Meinhardt, Josefine Radke, Carsten Dittmayer, Jonas Franz, Carolina Thomas, Ronja Mothes, Michael Laue, Julia Schneider, Sebastian Brünink, Selina Greuel, … Frank L. Heppner
Nature Neuroscience (2020-11-30) https://doi.org/fk46 DOI: 10.1038/s41593-020-00758-5 · PMID: 33257876 4.
Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young
Thomas J. Oxley, J. Mocco, Shahram Majidi, Christopher P. Kellner, Hazem Shoirah, I. Paul Singh, Reade A. De Leacy, Tomoyoshi Shigematsu, Travis R. Ladner, Kurt A. Yaeger, … Johanna T. Fifi
New England Journal of Medicine (2020-05-14) https://doi.org/ggtsjg DOI: 10.1056/nejmc2009787 · PMID: 32343504 · PMCID: PMC7207073 65.
Incidence of thrombotic complications in critically ill ICU patients with COVID-19
F. A. Klok, M. J. H. A. Kruip, N. J. M. van der Meer, M. S. Arbous, D. A. M. P. J. Gommers, K. M. Kant, F. H. J. Kaptein, J. van Paassen, M. A. M. Stals, M. V. Huisman, H. Endeman
Thrombosis Research (2020-07) https://doi.org/dt2q DOI: 10.1016/j.thromres.2020.04.013 · PMID: 32291094 · PMCID: PMC7146714 66.
Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19
Yan Zhang, Meng Xiao, Shulan Zhang, Peng Xia, Wei Cao, Wei Jiang, Huan Chen, Xin Ding, Hua Zhao, Hongmin Zhang, … Shuyang Zhang
New England Journal of Medicine (2020-04-23) https://doi.org/ggrgz7 DOI: 10.1056/nejmc2007575 · PMID: 32268022 · PMCID: PMC7161262 67.
Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia
Ning Tang, Dengju Li, Xiong Wang, Ziyong Sun
Journal of Thrombosis and Haemostasis (2020-04) https://doi.org/ggqxf6 DOI: 10.1111/jth.14768 · PMID: 32073213 · PMCID: PMC7166509 68.
Review: Viral infections and mechanisms of thrombosis and bleeding
M. Goeijenbier, M. van Wissen, C. van de Weg, E. Jong, V. E. A. Gerdes, J. C. M. Meijers, D. P. M. Brandjes, E. C. M. van Gorp
Journal of Medical Virology (2012-10) https://doi.org/f37tfr DOI: 10.1002/jmv.23354 · PMID: 22930518 · PMCID: PMC7166625 69.
Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia
Dennis McGonagle, James S O’Donnell, Kassem Sharif, Paul Emery, Charles Bridgewood
The Lancet Rheumatology (2020-07) https://doi.org/ggvd74 DOI: 10.1016/s2665-9913(20)30121-1 · PMID: 32835247 · PMCID: PMC7252093 70. “War to the knife” against thromboinflammation to protect endothelial function of COVID-19 patients
Gabriele Guglielmetti, Marco Quaglia, Pier Paolo Sainaghi, Luigi Mario Castello, Rosanna Vaschetto, Mario Pirisi, Francesco Della Corte, Gian Carlo Avanzi, Piero Stratta, Vincenzo Cantaluppi
Critical Care (2020-06-19) https://doi.org/gg35w7 DOI: 10.1186/s13054-020-03060-9 · PMID: 32560665 · PMCID: PMC7303575 71.
COVID-19 update: Covid-19-associated coagulopathy
Richard C. Becker ournal of Thrombosis and Thrombolysis (2020-05-15) https://doi.org/ggwpp5 DOI: 10.1007/s11239-020-02134-3 · PMID: 32415579 · PMCID: PMC7225095 72.
The complement system in COVID-19: friend and foe?
Anuja Java, Anthony J. Apicelli, M. Kathryn Liszewski, Ariella Coler-Reilly, John P. Atkinson, Alfred H. J. Kim, Hrishikesh S. Kulkarni
JCI Insight (2020-08-06) https://doi.org/gg4b5b DOI: 10.1172/jci.insight.140711 · PMID: 32554923 · PMCID: PMC7455060 73.
COVID-19, microangiopathy, hemostatic activation, and complement
Wen-Chao Song, Garret A. FitzGerald
Journal of Clinical Investigation (2020-06-22) https://doi.org/gg4b5c DOI: 10.1172/jci140183 · PMID: 32459663 · PMCID: PMC7410042 74.
Molecular biology of the cell
Bruce Alberts (editor)
Garland Science (2002) ISBN: 9780815332183 75.
Vander’s human physiology: the mechanisms of body function
Eric P Widmaier, Hershel Raff, Kevin T Strang
McGraw-Hill Higher Education (2008) ISBN: 9780071283663 76.
The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19?
Julia L. McKechnie, Catherine A. Blish
Cell Host & Microbe (2020-06) https://doi.org/gg28pq DOI: 10.1016/j.chom.2020.05.009 · PMID: 32464098 · PMCID: PMC7237895 77.
Inflammatory responses and inflammation-associated diseases in organs
Linlin Chen, Huidan Deng, Hengmin Cui, Jing Fang, Zhicai Zuo, Junliang Deng, Yinglun Li, Xun Wang, Ling Zhao
Oncotarget (2017-12-14) https://doi.org/ggps2p DOI: 10.18632/oncotarget.23208 · PMID: 29467962 · PMCID: PMC5805548 78.
Into the Eye of the Cytokine Storm
J. R. Tisoncik, M. J. Korth, C. P. Simmons, J. Farrar, T. R. Martin, M. G. Katze
Microbiology and Molecular Biology Reviews (2012-03-05) https://doi.org/f4n9h2 DOI: 10.1128/mmbr.05015-11 · PMID: 22390970 · PMCID: PMC3294426 79.
Cytokines, Inflammation, and Pain
Jun-Ming Zhang, Jianxiong An
International Anesthesiology Clinics (2007) https://doi.org/ft5b7h DOI: 10.1097/aia.0b013e318034194e · PMID: 17426506 · PMCID: PMC2785020 0.
Dynamic balance of pro- and anti-inflammatory signals controls disease and limits pathology
Joseph M. Cicchese, Stephanie Evans, Caitlin Hult, Louis R. Joslyn, Timothy Wessler, Jess A. Millar, Simeone Marino, Nicholas A. Cilfone, Joshua T. Mattila, Jennifer J. Linderman, Denise E. Kirschner
Immunological Reviews (2018-09) https://doi.org/gd4g4p DOI: 10.1111/imr.12671 · PMID: 30129209 · PMCID: PMC6292442 81.
Cytokine Dysregulation, Inflammation and Well-Being
Ilia J. Elenkov, Domenic G. Iezzoni, Adrian Daly, Alan G. Harris, George P. Chrousos
Neuroimmunomodulation (2005) https://doi.org/bsn7kn DOI: 10.1159/000087104 · PMID: 16166805 82.
Chronic inflammation in the etiology of disease across the life span
David Furman, Judith Campisi, Eric Verdin, Pedro Carrera-Bastos, Sasha Targ, Claudio Franceschi, Luigi Ferrucci, Derek W. Gilroy, Alessio Fasano, Gary W. Miller, … George M. Slavich
Nature Medicine (2019-12-05) https://doi.org/gghdcf DOI: 10.1038/s41591-019-0675-0 · PMID: 31806905 · PMCID: PMC7147972 83.
Inpatient care for septicemia or sepsis: a challenge for patients and hospitals.
Margaret Jean Hall, Sonja N Williams, Carol J DeFrances, Aleksandr Golosinskiy
NCHS data brief
Cytokine Balance in the Lungs of Patients with Acute Respiratory Distress Syndrome
WILLIAM Y. PARK, RICHARD B. GOODMAN, KENNETH P. STEINBERG, JOHN T. RUZINSKI, FRANK RADELLA, DAVID R. PARK, JEROME PUGIN, SHAWN J. SKERRETT, LEONARD D. HUDSON, THOMAS R. MARTIN
American Journal of Respiratory and Critical Care Medicine (2001-11-15) https://doi.org/ggqfq7 DOI: 10.1164/ajrccm.164.10.2104013 · PMID: 11734443 85.
Cytokine release syndrome
Alexander Shimabukuro-Vornhagen, Philipp Gödel, Marion Subklewe, Hans Joachim Stemmler, Hans Anton Schlößer, Max Schlaak, Matthias Kochanek, Boris Böll, Michael S. von Bergwelt-Baildon
Journal for ImmunoTherapy of Cancer (2018-06-15) https://doi.org/ghbncj DOI: 10.1186/s40425-018-0343-9 · PMID: 29907163 · PMCID: PMC6003181 86.
Understanding the Inflammatory Cytokine Response in Pneumonia and Sepsis
John A. Kellum
Archives of Internal Medicine (2007-08-13) https://doi.org/dbxb66 DOI: 10.1001/archinte.167.15.1655 · PMID: 17698689 · PMCID: PMC4495652 87.
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Jürgen Scheller, Athena Chalaris, Dirk Schmidt-Arras, Stefan Rose-John iochimica et Biophysica Acta (BBA) - Molecular Cell Research (2011-05) https://doi.org/cvn4nr DOI: 10.1016/j.bbamcr.2011.01.034 · PMID: 21296109 88.
The Role of Interleukin 6 During Viral Infections
Lauro Velazquez-Salinas, Antonio Verdugo-Rodriguez, Luis L. Rodriguez, Manuel V. Borca
Frontiers in Microbiology (2019-05-10) https://doi.org/ghbnck DOI: 10.3389/fmicb.2019.01057 · PMID: 31134045 · PMCID: PMC6524401 89.
Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2 + cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS L He, Y Ding, Q Zhang, X Che, Y He, H Shen, H Wang, Z Li, L Zhao, J Geng, … S Jiang
The Journal of Pathology (2006-11) https://doi.org/bwb8ns DOI: 10.1002/path.2067 · PMID: 17031779 90.
Up-regulation of IL-6 and TNF-α induced by SARS-coronavirus spike protein in murine macrophages via NF-κB pathway
Wei Wang, Linbai Ye, Li Ye, Baozong Li, Bo Gao, Yingchun Zeng, Lingbao Kong, Xiaonan Fang, Hong Zheng, Zhenghui Wu, Yinglong She
Virus Research (2007-09) https://doi.org/bm7m55 DOI: 10.1016/j.virusres.2007.02.007 · PMID: 17532082 · PMCID: PMC7114322 91.
COVID-19: consider cytokine storm syndromes and immunosuppression
Puja Mehta, Daniel F McAuley, Michael Brown, Emilie Sanchez, Rachel S Tattersall, Jessica J Manson
The Lancet (2020-03) https://doi.org/ggnzmc DOI: 10.1016/s0140-6736(20)30628-0 92.
Cytokine Storms: Understanding COVID-19
Nilam Mangalmurti, Christopher A. Hunter
Immunity (2020-07) https://doi.org/gg4fd7 DOI: 10.1016/j.immuni.2020.06.017 · PMID: 32610079 · PMCID: PMC7321048 93.
Is a “Cytokine Storm” Relevant to COVID-19?
Pratik Sinha, Michael A. Matthay, Carolyn S. Calfee
JAMA Internal Medicine (2020-09-01) https://doi.org/gg3k6r DOI: 10.1001/jamainternmed.2020.3313 · PMID: 32602883 94.
Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
Bingwen Liu, Min Li, Zhiguang Zhou, Xuan Guan, Yufei Xiang
Journal of Autoimmunity (2020-07) https://doi.org/ggr79c DOI: 10.1016/j.jaut.2020.102452 · PMID: 32291137 · PMCID: PMC7151347 95.
SARS-CoV-2 infection in primary schools in northern France: A retrospective cohort study in an area of high transmission
Arnaud Fontanet, Rebecca Grant, Laura Tondeur, Yoann Madec, Ludivine Grzelak, Isabelle ailleau, Marie-Noëlle Ungeheuer, Charlotte Renaudat, Sandrine Fernandes Pellerin, Lucie Kuhmel, … Bruno Hoen
Cold Spring Harbor Laboratory (2020-06-29) https://doi.org/gg87nn DOI: 10.1101/2020.06.25.20140178 96.
SARS-CoV-2 Infection in Children
Xiaoxia Lu, Liqiong Zhang, Hui Du, Jingjing Zhang, Yuan Y. Li, Jingyu Qu, Wenxin Zhang, Youjie Wang, Shuangshuang Bao, Ying Li, … Gary W. K. Wong
New England Journal of Medicine (2020-04-23) https://doi.org/ggpt2q DOI: 10.1056/nejmc2005073 · PMID: 32187458 · PMCID: PMC7121177 97.
Systematic review of COVID -
19 in children shows milder cases and a better prognosis than adults
Jonas F. Ludvigsson
Acta Paediatrica (2020-04-14) https://doi.org/ggq8wr DOI: 10.1111/apa.15270 · PMID: 32202343 · PMCID: PMC7228328 98.
Reopening schools during COVID-19
Ronan Lordan, Garret A. FitzGerald, Tilo Grosser
Science (2020-09-03) https://doi.org/ghsv9p DOI: 10.1126/science.abe5765 · PMID: 32883837 99.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents
Riccardo Castagnoli, Martina Votto, Amelia Licari, Ilaria Brambilla, Raffaele Bruno, Stefano Perlini, Francesca Rovida, Fausto Baldanti, Gian Luigi Marseglia
JAMA Pediatrics (2020-09-01) https://doi.org/dswz DOI: 10.1001/jamapediatrics.2020.1467 · PMID: 32320004 100.
Neurologic and Radiographic Findings Associated With COVID-19 Infection in Children
Omar Abdel-Mannan, Michael Eyre, Ulrike Löbel, Alasdair Bamford, Christin Eltze, Biju Hameed, Cheryl Hemingway, Yael Hacohen
JAMA Neurology (2020-11-01) https://doi.org/gg339f DOI: 10.1001/jamaneurol.2020.2687 · PMID: 32609336 · PMCID: PMC7330822 101.
Children with Covid-19 in Pediatric Emergency Departments in Italy
Niccolò Parri, Matteo Lenge, Danilo Buonsenso
New England Journal of Medicine (2020-07-09) https://doi.org/ggtp6z DOI: 10.1056/nejmc2007617 · PMID: 32356945 · PMCID: PMC7206930 102.
COVID-19 in 7780 pediatric patients: A systematic review
Ansel Hoang, Kevin Chorath, Axel Moreira, Mary Evans, Finn Burmeister-Morton, Fiona Burmeister, Rija Naqvi, Matthew Petershack, Alvaro Moreira
EClinicalMedicine (2020-07) https://doi.org/gg4hn2 DOI: 10.1016/j.eclinm.2020.100433 · PMID: 32766542 · PMCID: PMC7318942 03.
Multisystem Inflammatory Syndrome in Children During the Coronavirus 2019 Pandemic: A Case Series
Kathleen Chiotos, Hamid Bassiri, Edward M Behrens, Allison M Blatz, Joyce Chang, Caroline Diorio, Julie C Fitzgerald, Alexis Topjian, Audrey R Odom John
Journal of the Pediatric Infectious Diseases Society (2020-07) https://doi.org/ggx4pd DOI: 10.1093/jpids/piaa069 · PMID: 32463092 · PMCID: PMC7313950 104.
Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2
Elizabeth Whittaker, Alasdair Bamford, Julia Kenny, Myrsini Kaforou, Christine E. Jones, Priyen Shah, Padmanabhan Ramnarayan, Alain Fraisse, Owen Miller, Patrick Davies, … for the PIMS-TS Study Group and EUCLIDS and PERFORM Consortia
JAMA (2020-07-21) https://doi.org/gg2v75 DOI: 10.1001/jama.2020.10369 · PMID: 32511692 · PMCID: PMC7281356 105.
Toxic shock-like syndrome and COVID-19: Multisystem inflammatory syndrome in children (MIS-C)
Andrea G. Greene, Mona Saleh, Eric Roseman, Richard Sinert
The American Journal of Emergency Medicine (2020-11) https://doi.org/gg2586 DOI: 10.1016/j.ajem.2020.05.117 · PMID: 32532619 · PMCID: PMC7274960 106.
Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS–CoV-2
Caroline Diorio, Sarah E. Henrickson, Laura A. Vella, Kevin O. McNerney, Julie Chase, Chakkapong Burudpakdee, Jessica H. Lee, Cristina Jasen, Fran Balamuth, David M. Barrett, … Hamid Bassiri
Journal of Clinical Investigation (2020-10-05) https://doi.org/gg7mz2 DOI: 10.1172/jci140970 · PMID: 32730233 · PMCID: PMC7598044 107.
The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19
Camila Rosat Consiglio, Nicola Cotugno, Fabian Sardh, Christian Pou, Donato Amodio, Lucie Rodriguez, Ziyang Tan, Sonia Zicari, Alessandra Ruggiero, Giuseppe Rubens Pascucci, … Petter Brodin
Cell (2020-11) https://doi.org/d8fh DOI: 10.1016/j.cell.2020.09.016 · PMID: 32966765 · PMCID: PMC7474869 108.
Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic
Zahra Belhadjer, Mathilde Méot, Fanny Bajolle, Diala Khraiche, Antoine Legendre, Samya Abakka, Johanne Auriau, Marion Grimaud, Mehdi Oualha, Maurice Beghetti, … Damien Bonnet
Circulation (2020-08-04) https://doi.org/ggwkv6 DOI: 10.1161/circulationaha.120.048360 · PMID: 32418446 109.
An adult with Kawasaki-like multisystem inflammatory syndrome associated with COVID-19
Sheila Shaigany, Marlis Gnirke, Allison Guttmann, Hong Chong, Shane Meehan, Vanessa Raabe, Eddie Louie, Bruce Solitar, Alisa Femia he Lancet (2020-07) https://doi.org/gg4sd6 DOI: 10.1016/s0140-6736(20)31526-9 · PMID: 32659211 · PMCID: PMC7351414 110.
COVID-19 associated Kawasaki-like multisystem inflammatory disease in an adult
Sabrina Sokolovsky, Parita Soni, Taryn Hoffman, Philip Kahn, Joshua Scheers-Masters
The American Journal of Emergency Medicine (2021-01) https://doi.org/gg5tf4 DOI: 10.1016/j.ajem.2020.06.053 · PMID: 32631771 · PMCID: PMC7315983 111.
A systems approach to infectious disease
Manon Eckhardt, Judd F. Hultquist, Robyn M. Kaake, Ruth Hüttenhain, Nevan J. Krogan
Nature Reviews Genetics (2020-02-14) https://doi.org/ggnv63 DOI: 10.1038/s41576-020-0212-5 · PMID: 32060427 112.
Differential expression of serum/plasma proteins in various infectious diseases: Specific or nonspecific signatures
Sandipan Ray, Sandip K. Patel, Vipin Kumar, Jagruti Damahe, Sanjeeva Srivastava
PROTEOMICS - Clinical Applications (2014-02) https://doi.org/f2px3h DOI: 10.1002/prca.201300074 · PMID: 24293340 113.
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
Daniel Blanco-Melo, Benjamin E. Nilsson-Payant, Wen-Chun Liu, Skyler Uhl, Daisy Hoagland, Rasmus Møller, Tristan X. Jordan, Kohei Oishi, Maryline Panis, David Sachs, … Benjamin R. tenOever
Cell (2020-05) https://doi.org/ggw5tq DOI: 10.1016/j.cell.2020.04.026 · PMID: 32416070 · PMCID: PMC7227586 114.
SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant
Yoriyuki Konno, Izumi Kimura, Keiya Uriu, Masaya Fukushi, Takashi Irie, Yoshio Koyanagi, Daniel Sauter, Robert J. Gifford, So Nakagawa, Kei Sato
Cell Reports (2020-09) https://doi.org/ghvf8j DOI: 10.1016/j.celrep.2020.108185 · PMID: 32941788 · PMCID: PMC7473339 115.
Bulk and single-cell gene expression profiling of SARS-CoV-2 infected human cell lines identifies molecular targets for therapeutic intervention
Wyler Emanuel, Mösbauer Kirstin, Franke Vedran, Diag Asija, Gottula Lina Theresa, Arsie Roberto, Klironomos Filippos, Koppstein David, Ayoub Salah, Buccitelli Christopher, … Landthaler Markus
Cold Spring Harbor Laboratory (2020-05-05) https://doi.org/ggxd2g DOI: 10.1101/2020.05.05.079194 116.
Isolation and characterization of SARS-CoV-2 from the first US COVID-19 patient
Jennifer Harcourt, Azaibi Tamin, Xiaoyan Lu, Shifaq Kamili, Senthil Kumar. Sakthivel, Janna Murray, Krista Queen, Ying Tao, Clinton R. Paden, Jing Zhang, … Natalie J. Thornburg
Cold Spring Harbor Laboratory (2020-03-07) https://doi.org/gg2fkm DOI: 10.1101/2020.03.02.972935 · PMID: 32511316 · PMCID: PMC7239045 17.
Proteomics of SARS-CoV-2-infected host cells reveals therapy targets
Denisa Bojkova, Kevin Klann, Benjamin Koch, Marek Widera, David Krause, Sandra Ciesek, Jindrich Cinatl, Christian Münch
Nature (2020-05-14) https://doi.org/dw7s DOI: 10.1038/s41586-020-2332-7 · PMID: 32408336 118.
Potent human neutralizing antibodies elicited by SARS-CoV-2 infection
Bin Ju, Qi Zhang, Xiangyang Ge, Ruoke Wang, Jiazhen Yu, Sisi Shan, Bing Zhou, Shuo Song, Xian Tang, Jinfang Yu, … Linqi Zhang
Cold Spring Harbor Laboratory (2020-03-26) https://doi.org/ggp7t4 DOI: 10.1101/2020.03.21.990770 119.
Plasma proteome of severe acute respiratory syndrome analyzed by two-dimensional gel electrophoresis and mass spectrometry
J.-H. Chen, Y.-W. Chang, C.-W. Yao, T.-S. Chiueh, S.-C. Huang, K.-Y. Chien, A. Chen, F.-Y. Chang, C.-H. Wong, Y.-J. Chen
Proceedings of the National Academy of Sciences (2004-11-30) https://doi.org/dtv8sx DOI: 10.1073/pnas.0407992101 · PMID: 15572443 · PMCID: PMC535397 120.
Analysis of multimerization of the SARS coronavirus nucleocapsid protein
Runtao He, Frederick Dobie, Melissa Ballantine, Andrew Leeson, Yan Li, Nathalie Bastien, Todd Cutts, Anton Andonov, Jingxin Cao, Timothy F. Booth, … Xuguang Li
Biochemical and Biophysical Research Communications (2004-04) https://doi.org/dbfwr9 DOI: 10.1016/j.bbrc.2004.02.074 · PMID: 15020242 · PMCID: PMC7111152 121.
UniProt: a worldwide hub of protein knowledge
The UniProt Consortium
Nucleic Acids Research (2019-01-08) https://doi.org/gfwqck DOI: 10.1093/nar/gky1049 · PMID: 30395287 · PMCID: PMC6323992 122.
Home - Genome - NCBI
The Immune Epitope Database (IEDB): 2018 update
Randi Vita, Swapnil Mahajan, James A Overton, Sandeep Kumar Dhanda, Sheridan Martini, Jason R Cantrell, Daniel K Wheeler, Alessandro Sette, Bjoern Peters
Nucleic Acids Research (2019-01-08) https://doi.org/gfhz6n DOI: 10.1093/nar/gky1006 · PMID: 30357391 · PMCID: PMC6324067 124.
ViPR: an open bioinformatics database and analysis resource for virology research
Brett E. Pickett, Eva L. Sadat, Yun Zhang, Jyothi M. Noronha, R. Burke Squires, Victoria Hunt, Mengya Liu, Sanjeev Kumar, Sam Zaremba, Zhiping Gu, … Richard H. Scheuermann
Nucleic Acids Research (2012-01) https://doi.org/c3tds5 DOI: 10.1093/nar/gkr859 · PMID: 22006842 · PMCID: PMC3245011 125.
A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing
David E. Gordon, Gwendolyn M. Jang, Mehdi Bouhaddou, Jiewei Xu, Kirsten Obernier, Matthew . O’Meara, Jeffrey Z. Guo, Danielle L. Swaney, Tia A. Tummino, Ruth Hüttenhain, … Nevan J. Krogan
Cold Spring Harbor Laboratory (2020-03-22) https://doi.org/ggpptg DOI: 10.1101/2020.03.22.002386 · PMID: 32511329 126.
Protein Palmitoylation and Its Role in Bacterial and Viral Infections
Justyna Sobocińska, Paula Roszczenko-Jasińska, Anna Ciesielska, Katarzyna Kwiatkowska
Frontiers in Immunology (2018-01-19) https://doi.org/gcxpp2 DOI: 10.3389/fimmu.2017.02003 · PMID: 29403483 · PMCID: PMC5780409 127.
Virus-host interactome and proteomic survey of PMBCs from COVID-19 patients reveal potential virulence factors influencing SARS-CoV-2 pathogenesis
Jingjiao Li, Mingquan Guo, Xiaoxu Tian, Chengrong Liu, Xin Wang, Xing Yang, Ping Wu, Zixuan Xiao, Yafei Qu, Yue Yin, … Qiming Liang
Cold Spring Harbor Laboratory (2020-04-02) https://doi.org/ggrgbv DOI: 10.1101/2020.03.31.019216 128.
The Nuclear Factor NF- B Pathway in Inflammation
T. Lawrence
Cold Spring Harbor Perspectives in Biology (2009-10-07) https://doi.org/fptfvp DOI: 10.1101/cshperspect.a001651 · PMID: 20457564 · PMCID: PMC2882124 129.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) envelope (E) protein harbors a conserved BH3-like sequence
Vincent Navratil, Loïc Lionnard, Sonia Longhi, J. Marie Hardwick, Christophe Combet, Abdel Aouacheria
Cold Spring Harbor Laboratory (2020-06-09) https://doi.org/ggrp43 DOI: 10.1101/2020.04.09.033522 130.
Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor
F. Li
Science (2005-09-16) https://doi.org/fww324 DOI: 10.1126/science.1116480 · PMID: 16166518 131.
Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2
Renhong Yan, Yuanyuan Zhang, Yaning Li, Lu Xia, Yingying Guo, Qiang Zhou
Science (2020-03-27) https://doi.org/ggpxc8 DOI: 10.1126/science.abb2762 · PMID: 32132184 · PMCID: PMC7164635 132.
Structural basis of receptor recognition by SARS-CoV-2
Jian Shang, Gang Ye, Ke Shi, Yushun Wan, Chuming Luo, Hideki Aihara, Qibin Geng, Ashley Auerbach, Fang Li
Nature (2020-03-30) https://doi.org/ggqspv DOI: 10.1038/s41586-020-2179-y · PMID: 32225175 33.
Crystal structure of the 2019-nCoV spike receptor-binding domain bound with the ACE2 receptor
Jun Lan, Jiwan Ge, Jinfang Yu, Sisi Shan, Huan Zhou, Shilong Fan, Qi Zhang, Xuanling Shi, Qisheng Wang, Linqi Zhang, Xinquan Wang
Cold Spring Harbor Laboratory (2020-02-20) https://doi.org/ggqzp5 DOI: 10.1101/2020.02.19.956235 134.
Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2
Qihui Wang, Yanfang Zhang, Lili Wu, Sheng Niu, Chunli Song, Zengyuan Zhang, Guangwen Lu, Chengpeng Qiao, Yu Hu, Kwok-Yung Yuen, … Jianxun Qi
Cell (2020-05) https://doi.org/ggr2cz DOI: 10.1016/j.cell.2020.03.045 · PMID: 32275855 · PMCID: PMC7144619 135.
Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus
Yushun Wan, Jian Shang, Rachel Graham, Ralph S. Baric, Fang Li
Journal of Virology (2020-03-17) https://doi.org/ggjvwn DOI: 10.1128/jvi.00127-20 · PMID: 31996437 · PMCID: PMC7081895 136.
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Peng Zhou, Xing-Lou Yang, Xian-Guang Wang, Ben Hu, Lei Zhang, Wei Zhang, Hao-Rui Si, Yan Zhu, Bei Li, Chao-Lin Huang, … Zheng-Li Shi
Nature (2020-02-03) https://doi.org/ggj5cg DOI: 10.1038/s41586-020-2012-7 · PMID: 32015507 · PMCID: PMC7095418 137.
Structure of the Hemagglutinin Precursor Cleavage Site, a Determinant of Influenza Pathogenicity and the Origin of the Labile Conformation
Jue Chen, Kon Ho Lee, David A Steinhauer, David J Stevens, John J Skehel, Don C Wiley
Cell (1998-10) https://doi.org/bvgh5b DOI: 10.1016/s0092-8674(00)81771-7 138.
Role of Hemagglutinin Cleavage for the Pathogenicity of Influenza Virus
David A. Steinhauer
Virology (1999-05) https://doi.org/fw3jz4 DOI: 10.1006/viro.1999.9716 · PMID: 10329563 139.
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
Bette Korber, Will M. Fischer, Sandrasegaram Gnanakaran, Hyejin Yoon, James Theiler, Werner Abfalterer, Nick Hengartner, Elena E. Giorgi, Tanmoy Bhattacharya, Brian Foley, … Matthew D. Wyles
Cell (2020-08) https://doi.org/gg3wqn DOI: 10.1016/j.cell.2020.06.043 · PMID: 32697968 · PMCID: PMC7332439 140.
Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant
Leonid Yurkovetskiy, Xue Wang, Kristen E. Pascal, Christopher Tomkins-Tinch, Thomas P. Nyalile, Yetao Wang, Alina Baum, William E. Diehl, Ann Dauphin, Claudia Carbone, … Jeremy uban
Cell (2020-10) https://doi.org/ghkt47 DOI: 10.1016/j.cell.2020.09.032 · PMID: 32991842 · PMCID: PMC7492024 141.
Emergence of a new SARS-CoV-2 variant in the UK
Julian W Tang, Paul A Tambyah, David SC Hui
Journal of Infection (2020-12) https://doi.org/ghtg2k DOI: 10.1016/j.jinf.2020.12.024 · PMID: 33383088 · PMCID: PMC7834693 142.
WHO | SARS-CoV-2 Variant – United Kingdom of Great Britain and Northern Ireland
SARS-CoV-2 Variant Under Investigation 202012/01 has more than twofold replicative advantage
Frederic Grabowski, Grzegorz Preibisch, Marek Kochańczyk, Tomasz Lipniacki
Cold Spring Harbor Laboratory (2021-01-04) https://doi.org/ghtzw3 DOI: 10.1101/2020.12.28.20248906 144.
Controversy around airborne versus droplet transmission of respiratory viruses
Eunice Y. C. Shiu, Nancy H. L. Leung, Benjamin J. Cowling
Current Opinion in Infectious Diseases (2019-08) https://doi.org/ggbwdb DOI: 10.1097/qco.0000000000000563 145.
Viral infections acquired indoors through airborne, droplet or contact transmission.
Giuseppina La Rosa, Marta Fratini, Simonetta Della Libera, Marcello Iaconelli, Michele Muscillo
Annali dell’Istituto superiore di sanita
Transmission of SARS-CoV-2: implications for infection prevention precautions
Questioning Aerosol Transmission of Influenza
Camille Lemieux, Gabrielle Brankston, Leah Gitterman, Zahir Hirji, Michael Gardam
Emerging Infectious Diseases (2007-01) https://doi.org/c2skj8 DOI: 10.3201/eid1301.061202 · PMID: 17370541 · PMCID: PMC2725811 148.
Assessing the Dynamics and Control of Droplet- and Aerosol-Transmitted Influenza Using an Indoor Positioning System
Timo Smieszek, Gianrocco Lazzari, Marcel Salathé
Scientific Reports (2019-02-18) https://doi.org/ggnqbc DOI: 10.1038/s41598-019-38825-y · PMID: 30778136 · PMCID: PMC6379436 149.
Influenza A virus transmission via respiratory aerosols or droplets as it relates to pandemic potential
Mathilde Richard, Ron A. M. Fouchier
EMS Microbiology Reviews (2016-01) https://doi.org/f8cp4h DOI: 10.1093/femsre/fuv039 · PMID: 26385895 · PMCID: PMC5006288 150.
Coronavirus Pathogenesis
Susan R. Weiss, Julian L. Leibowitz
Advances in Virus Research (2011) https://doi.org/ggvvd7 DOI: 10.1016/b978-0-12-385885-6.00009-2 · PMID: 22094080 · PMCID: PMC7149603 151.
SARS and MERS: recent insights into emerging coronaviruses
Emmie de Wit, Neeltje van Doremalen, Darryl Falzarano, Vincent J. Munster
Nature Reviews Microbiology (2016-06-27) https://doi.org/f8v5cv DOI: 10.1038/nrmicro.2016.81 · PMID: 27344959 · PMCID: PMC7097822 152.
Role of fomites in SARS transmission during the largest hospital outbreak in Hong Kong
Shenglan Xiao, Yuguo Li, Tze-wai Wong, David S. C. Hui
PLOS ONE (2017-07-20) https://doi.org/gbpgv7 DOI: 10.1371/journal.pone.0181558 · PMID: 28727803 · PMCID: PMC5519164 153.
Stability of Middle East respiratory syndrome coronavirus (MERS-CoV) under different environmental conditions
N van Doremalen, T Bushmaker, VJ Munster
Eurosurveillance (2013-09-19) https://doi.org/ggnnjt DOI: 10.2807/1560-7917.es2013.18.38.20590 · PMID: 24084338 154.
MERS coronavirus: diagnostics, epidemiology and transmission
Ian M. Mackay, Katherine E. Arden
Virology Journal (2015-12-22) https://doi.org/f745px DOI: 10.1186/s12985-015-0439-5 · PMID: 26695637 · PMCID: PMC4687373 155.
Transmission routes of 2019-nCoV and controls in dental practice
Xian Peng, Xin Xu, Yuqing Li, Lei Cheng, Xuedong Zhou, Biao Ren
International Journal of Oral Science (2020-03-03) https://doi.org/ggnf47 DOI: 10.1038/s41368-020-0075-9 · PMID: 32127517 · PMCID: PMC7054527 156.
Reducing transmission of SARS-CoV-2
Kimberly A. Prather, Chia C. Wang, Robert T. Schooley
Science (2020-06-26) https://doi.org/ggxp9w DOI: 10.1126/science.abc6197 · PMID: 32461212 157.
Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1
Neeltje van Doremalen, Trenton Bushmaker, Dylan H. Morris, Myndi G. Holbrook, Amandine Gamble, Brandi N. Williamson, Azaibi Tamin, Jennifer L. Harcourt, Natalie J. Thornburg, Susan I. Gerber, … Vincent J. Munster
New England Journal of Medicine (2020-04-16) https://doi.org/ggn88w DOI: 10.1056/nejmc2004973 · PMID: 32182409 · PMCID: PMC7121658 58.
It Is Time to Address Airborne Transmission of Coronavirus Disease 2019 (COVID-19)
Lidia Morawska, Donald K Milton
Clinical Infectious Diseases (2020-07-06) https://doi.org/gg34zn DOI: 10.1093/cid/ciaa939 · PMID: 32628269 · PMCID: PMC7454469 159.
Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals
Yuan Liu, Zhi Ning, Yu Chen, Ming Guo, Yingle Liu, Nirmal Kumar Gali, Li Sun, Yusen Duan, Jing Cai, Dane Westerdahl, … Ke Lan
Nature (2020-04-27) https://doi.org/ggtgng DOI: 10.1038/s41586-020-2271-3 · PMID: 32340022 160.
Airborne Transmission of SARS-CoV-2
Michael Klompas, Meghan A. Baker, Chanu Rhee
JAMA (2020-08-04) https://doi.org/gg4ttq DOI: 10.1001/jama.2020.12458 161.
Exaggerated risk of transmission of COVID-19 by fomites
Emanuel Goldman
The Lancet Infectious Diseases (2020-08) https://doi.org/gg6br7 DOI: 10.1016/s1473-3099(20)30561-2 · PMID: 32628907 · PMCID: PMC7333993 162.
Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China
Zhiliang Hu, Ci Song, Chuanjun Xu, Guangfu Jin, Yaling Chen, Xin Xu, Hongxia Ma, Wei Chen, Yuan Lin, Yishan Zheng, … Hongbing Shen
Science China Life Sciences (2020-03-04) https://doi.org/dqbn DOI: 10.1007/s11427-020-1661-4 · PMID: 32146694 · PMCID: PMC7088568 163.
Evidence for transmission of COVID-19 prior to symptom onset
Lauren C Tindale, Jessica E Stockdale, Michelle Coombe, Emma S Garlock, Wing Yin Venus Lau, Manu Saraswat, Louxin Zhang, Dongxuan Chen, Jacco Wallinga, Caroline Colijn eLife (2020-06-22) https://doi.org/gg6dtw DOI: 10.7554/elife.57149 · PMID: 32568070 · PMCID: PMC7386904 164.
Time Kinetics of Viral Clearance and Resolution of Symptoms in Novel Coronavirus Infection
De Chang, Guoxin Mo, Xin Yuan, Yi Tao, Xiaohua Peng, Fu-Sheng Wang, Lixin Xie, Lokesh Sharma, Charles S. Dela Cruz, Enqiang Qin
American Journal of Respiratory and Critical Care Medicine (2020-05-01) https://doi.org/ggq8xs DOI: 10.1164/rccm.202003-0524le · PMID: 32200654 · PMCID: PMC7193851 165.
Temporal dynamics in viral shedding and transmissibility of COVID-19
Xi He, Eric H. Y. Lau, Peng Wu, Xilong Deng, Jian Wang, Xinxin Hao, Yiu Chung Lau, Jessica Y. Wong, Yujuan Guan, Xinghua Tan, … Gabriel M. Leung
Nature Medicine (2020-04-15) https://doi.org/ggr99q DOI: 10.1038/s41591-020-0869-5 · PMID: 32296168 66.
COVID-19 and Your Health
CDC
Centers for Disease Control and Prevention
Virological assessment of hospitalized patients with COVID-2019
Roman Wölfel, Victor M. Corman, Wolfgang Guggemos, Michael Seilmaier, Sabine Zange, Marcel A. Müller, Daniela Niemeyer, Terry C. Jones, Patrick Vollmar, Camilla Rothe, … Clemens Wendtner
Nature (2020-04-01) https://doi.org/ggqrv7 DOI: 10.1038/s41586-020-2196-x · PMID: 32235945 168.
Clinical predictors and timing of cessation of viral RNA shedding in patients with COVID-19
Cristina Corsini Campioli, Edison Cano Cevallos, Mariam Assi, Robin Patel, Matthew J. Binnicker, John C. O’Horo
Journal of Clinical Virology (2020-09) https://doi.org/gg7m96 DOI: 10.1016/j.jcv.2020.104577 · PMID: 32777762 · PMCID: PMC7405830 169.
Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility
Melissa M. Arons, Kelly M. Hatfield, Sujan C. Reddy, Anne Kimball, Allison James, Jesica R. Jacobs, Joanne Taylor, Kevin Spicer, Ana C. Bardossy, Lisa P. Oakley, … John A. Jernigan
New England Journal of Medicine (2020-05-28) https://doi.org/ggszfg DOI: 10.1056/nejmoa2008457 · PMID: 32329971 · PMCID: PMC7200056 170.
Prevalence of SARS-CoV-2 Infection in Residents of a Large Homeless Shelter in Boston
Travis P. Baggett, Harrison Keyes, Nora Sporn, Jessie M. Gaeta
JAMA (2020-06-02) https://doi.org/ggtsh3 DOI: 10.1001/jama.2020.6887 · PMID: 32338732 · PMCID: PMC7186911 171.
Presumed Asymptomatic Carrier Transmission of COVID-19
Yan Bai, Lingsheng Yao, Tao Wei, Fei Tian, Dong-Yan Jin, Lijuan Chen, Meiyun Wang
JAMA (2020-04-14) https://doi.org/ggmbs8 DOI: 10.1001/jama.2020.2565 · PMID: 32083643 · PMCID: PMC7042844 172.
Transmission of COVID-19 in the terminal stages of the incubation period: A familial cluster
Peng Li, Ji-Bo Fu, Ke-Feng Li, Jie-Nan Liu, Hong-Ling Wang, Lei-Jie Liu, Yan Chen, Yong-Li Zhang, She-Lan Liu, An Tang, … Jian-Bo Yan
International Journal of Infectious Diseases (2020-07) https://doi.org/ggq844 DOI: 10.1016/j.ijid.2020.03.027 · PMID: 32194239 · PMCID: PMC7264481 173.
A Cohort of SARS-CoV-2 Infected Asymptomatic and Pre-Symptomatic Contacts from COVID-19 Contact Tracing in Hubei Province, China: Short-Term Outcomes
Peng Zhang, Fei Tian, Yuan Wan, Jing Cai, Zhengmin Qian, Ran Wu, Yunquan Zhang, Shiyu hang, Huan Li, Mingyan Li, … Hualiang Lin
SSRN Electronic Journal (2020) https://doi.org/ghf3n2 DOI: 10.2139/ssrn.3678556 174.
Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020
Kenji Mizumoto, Katsushi Kagaya, Alexander Zarebski, Gerardo Chowell
Eurosurveillance (2020-03-12) https://doi.org/ggn4bd DOI: 10.2807/1560-7917.es.2020.25.10.2000180 · PMID: 32183930 · PMCID: PMC7078829 175.
Estimated prevalence and viral transmissibility in subjects with asymptomatic SARS-CoV-2 infections in Wuhan, China
Kang Zhang, Weiwei Tong, Xinghuan Wang, Johnson Yiu-Nam Lau
Precision Clinical Medicine (2020-12) https://doi.org/ghjmks DOI: 10.1093/pcmedi/pbaa032 · PMCID: PMC7499683 176.
Investigation of SARS-CoV-2 outbreaks in six care homes in London, April 2020
Shamez N Ladhani, J.Yimmy Chow, Roshni Janarthanan, Jonathan Fok, Emma Crawley-Boevey, Amoolya Vusirikala, Elena Fernandez, Marina Sanchez Perez, Suzanne Tang, Kate Dun-Campbell, … Maria Zambon
EClinicalMedicine (2020-09) https://doi.org/ghbj9v DOI: 10.1016/j.eclinm.2020.100533 · PMID: 32923993 · PMCID: PMC7480335 177.
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Quan-Xin Long, Xiao-Jun Tang, Qiu-Lin Shi, Qin Li, Hai-Jun Deng, Jun Yuan, Jie-Li Hu, Wei Xu, Yong Zhang, Fa-Jin Lv, … Ai-Long Huang
Nature Medicine (2020-06-18) https://doi.org/gg26dx DOI: 10.1038/s41591-020-0965-6 · PMID: 32555424 178.
Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo’
Enrico Lavezzo, Elisa Franchin, Constanze Ciavarella, Gina Cuomo-Dannenburg, Luisa Barzon, Claudia Del Vecchio, Lucia Rossi, Riccardo Manganelli, Arianna Loregian, Nicolò Navarin, … Imperial College COVID-19 Response Team
Nature (2020-06-30) https://doi.org/gg3w87 DOI: 10.1038/s41586-020-2488-1 · PMID: 32604404 179.
A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates
Gideon Meyerowitz-Katz, Lea Merone
International Journal of Infectious Diseases (2020-12) https://doi.org/ghgjpw DOI: 10.1016/j.ijid.2020.09.1464 · PMID: 33007452 · PMCID: PMC7524446 180.
Global Covid-19 Case Fatality Rates
Estimating the Global Infection Fatality Rate of COVID-19
Richard Grewelle, Giulio De Leo
Cold Spring Harbor Laboratory (2020-05-18) https://doi.org/ghbvcj DOI: 10.1101/2020.05.11.20098780 182.
Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City
Daniel Stadlbauer, Jessica Tan, Kaijun Jiang, Matthew M. Hernandez, Shelcie Fabre, Fatima Amanat, Catherine Teo, Guha Asthagiri Arunkumar, Meagan McMahon, Christina Capuano, … Florian Krammer
Nature (2020-11-03) https://doi.org/ghhtq9 DOI: 10.1038/s41586-020-2912-6 · PMID: 33142304 183.
What do we know about the risk of dying from COVID-19?
Our World in Data https://ourworldindata.org/covid-mortality-risk 184.
The concept of R o in epidemic theory J. A. P. Heesterbeek, K. Dietz
Statistica Neerlandica (1996-03) https://doi.org/d29ch4 DOI: 10.1111/j.1467-9574.1996.tb01482.x 185.
Modeling infectious diseases in humans and animals
Matthew James Keeling, Pejman Rohani
Princeton University Press (2008) ISBN: 9780691116174 186.
A contribution to the mathematical theory of epidemics
Proceedings of the Royal Society of London. Series A, Containing Papers of a Mathematical and Physical Character (1997-01) https://doi.org/fwx2qw DOI: 10.1098/rspa.1927.0118 187.
Population biology of infectious diseases: Part I
Roy M. Anderson, Robert M. May
Nature (1979-08-01) https://doi.org/b6z9hc DOI: 10.1038/280361a0 · PMID: 460412 188.
Modeling infectious disease dynamics
Sarah Cobey
Science (2020-05-15) https://doi.org/ggsztw DOI: 10.1126/science.abb5659 · PMID: 32332062 189.
Theoretical ecology: principles and applications
Robert M. May, Angela R. McLean (editors)
Oxford University Press (2007) ISBN: 9780199209989 90.
Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study
Joseph T Wu, Kathy Leung, Gabriel M Leung
The Lancet (2020-02) https://doi.org/ggjvr7 DOI: 10.1016/s0140-6736(20)30260-9 191.
The reproductive number of COVID-19 is higher compared to SARS coronavirus
Ying Liu, Albert A Gayle, Annelies Wilder-Smith, Joacim Rocklöv
Journal of Travel Medicine (2020-03) https://doi.org/ggnntv DOI: 10.1093/jtm/taaa021 · PMID: 32052846 · PMCID: PMC7074654 192.
Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2)
Ruiyun Li, Sen Pei, Bin Chen, Yimeng Song, Tao Zhang, Wan Yang, Jeffrey Shaman
Science (2020-05-01) https://doi.org/ggn6c2 DOI: 10.1126/science.abb3221 · PMID: 32179701 193.
Epidemiological parameters of coronavirus disease 2019: a pooled analysis of publicly reported individual data of 1155 cases from seven countries
Shujuan Ma, Jiayue Zhang, Minyan Zeng, Qingping Yun, Wei Guo, Yixiang Zheng, Shi Zhao, Maggie H. Wang, Zuyao Yang
Cold Spring Harbor Laboratory (2020-03-24) https://doi.org/ggqhzz DOI: 10.1101/2020.03.21.20040329 194.
Early Transmissibility Assessment of a Novel Coronavirus in Wuhan, China
Maimuna Majumder, Kenneth D. Mandl
SSRN Electronic Journal (2020) https://doi.org/ggqhz3 DOI: 10.2139/ssrn.3524675 · PMID: 32714102 195.
Time-varying transmission dynamics of Novel Coronavirus Pneumonia in China
Tao Liu, Jianxiong Hu, Jianpeng Xiao, Guanhao He, Min Kang, Zuhua Rong, Lifeng Lin, Haojie Zhong, Qiong Huang, Aiping Deng, … Wenjun Ma
Cold Spring Harbor Laboratory (2020-02-13) https://doi.org/dkx9 DOI: 10.1101/2020.01.25.919787 196.
Estimation of the reproductive number of novel coronavirus (COVID-19) and the probable outbreak size on the Diamond Princess cruise ship: A data-driven analysis
Sheng Zhang, MengYuan Diao, Wenbo Yu, Lei Pei, Zhaofen Lin, Dechang Chen
International Journal of Infectious Diseases (2020-04) https://doi.org/ggpx56 DOI: 10.1016/j.ijid.2020.02.033 · PMID: 32097725 · PMCID: PMC7110591 197.
Estimation of the Transmission Risk of the 2019-nCoV and Its Implication for Public Health Interventions
Biao Tang, Xia Wang, Qian Li, Nicola Luigi Bragazzi, Sanyi Tang, Yanni Xiao, Jianhong Wu
Journal of Clinical Medicine (2020-02-07) https://doi.org/ggmkf4 DOI: 10.3390/jcm9020462 · PMID: 32046137 · PMCID: PMC7074281 98.
Estimating the effective reproduction number of the 2019-nCoV in China
Zhidong Cao, Qingpeng Zhang, Xin Lu, Dirk Pfeiffer, Zhongwei Jia, Hongbing Song, Daniel Dajun Zeng medRxiv
Modelling the epidemic trend of the 2019 novel coronavirus outbreak in China
Mingwang Shen, Zhihang Peng, Yanni Xiao, Lei Zhang
Cold Spring Harbor Laboratory (2020-01-25) https://doi.org/ggqhzw DOI: 10.1101/2020.01.23.916726 200.
Novel coronavirus 2019-nCoV: early estimation of epidemiological parameters and epidemic predictions
Jonathan M. Read, Jessica R. E. Bridgen, Derek A. T. Cummings, Antonia Ho, Chris P. Jewell
Cold Spring Harbor Laboratory (2020-01-28) https://doi.org/dkzb DOI: 10.1101/2020.01.23.20018549 201.
Using early data to estimate the actual infection fatality ratio from COVID-19 in France
Lionel Roques, Etienne Klein, Julien Papaïx, Antoine Sar, Samuel Soubeyrand
Cold Spring Harbor Laboratory (2020-05-07) https://doi.org/ggqhz2 DOI: 10.1101/2020.03.22.20040915 202.
Potential roles of social distancing in mitigating the spread of coronavirus disease 2019 (COVID-19) in South Korea
Sang Woo Park, Kaiyuan Sun, Cécile Viboud, Bryan T Grenfell, Jonathan Dushoff
GitHub (2020) https://github.com/parksw3/Korea-analysis/blob/master/v1/korea.pdf 203.
Early dynamics of transmission and control of COVID-19: a mathematical modelling study
Adam J Kucharski, Timothy W Russell, Charlie Diamond, Yang Liu, John Edmunds, Sebastian Funk, Rosalind M Eggo, Fiona Sun, Mark Jit, James D Munday, … Stefan Flasche
The Lancet Infectious Diseases (2020-05) https://doi.org/ggptcf DOI: 10.1016/s1473-3099(20)30144-4 204.
Estimating the reproduction number of COVID-19 in Iran using epidemic modeling
Ebrahim Sahafizadeh, Samaneh Sartoli
Cold Spring Harbor Laboratory (2020-04-23) https://doi.org/ggqhzx DOI: 10.1101/2020.03.20.20038422 205.
Report 13: Estimating the number of infections and the impact of non-pharmaceutical interventions on COVID-19 in 11 European countries
S Flaxman, S Mishra, A Gandy, H Unwin, H Coupland, T Mellan, H Zhu, T Berah, J Eaton, P Perez Guzman, … S Bhatt
Imperial College London (2020-03-30) https://doi.org/ggrbmf DOI: 10.25561/77731 06.
Projecting hospital utilization during the COVID-19 outbreaks in the United States
Seyed M. Moghadas, Affan Shoukat, Meagan C. Fitzpatrick, Chad R. Wells, Pratha Sah, Abhishek Pandey, Jeffrey D. Sachs, Zheng Wang, Lauren A. Meyers, Burton H. Singer, Alison P. Galvani
Proceedings of the National Academy of Sciences (2020-04-21) https://doi.org/ggq7jc DOI: 10.1073/pnas.2004064117 · PMID: 32245814 · PMCID: PMC7183199 207.
The effect of control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: a modelling study
Kiesha Prem, Yang Liu, Timothy W Russell, Adam J Kucharski, Rosalind M Eggo, Nicholas Davies, Mark Jit, Petra Klepac, Stefan Flasche, Samuel Clifford, … Joel Hellewell
The Lancet Public Health (2020-05) https://doi.org/ggp3xq DOI: 10.1016/s2468-2667(20)30073-6 · PMID: 32220655 · PMCID: PMC7158905 208.
Spread and dynamics of the COVID-19 epidemic in Italy: Effects of emergency containment measures
Marino Gatto, Enrico Bertuzzo, Lorenzo Mari, Stefano Miccoli, Luca Carraro, Renato Casagrandi, Andrea Rinaldo
Proceedings of the National Academy of Sciences (2020-05-12) https://doi.org/ggv4j6 DOI: 10.1073/pnas.2004978117 · PMID: 32327608 · PMCID: PMC7229754 209.
Covid-19: Temporal variation in transmission during the COVID-19 outbreak
EpiForecasts and the CMMID Covid working group https://epiforecasts.io/covid/ 210.
Rt COVID-19
Kevin Systrom, Thomas Vladeck, Mike Krieger https://rt.live/ 211.
Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant
Maria Pachetti, Bruna Marini, Francesca Benedetti, Fabiola Giudici, Elisabetta Mauro, Paola Storici, Claudio Masciovecchio, Silvia Angeletti, Massimo Ciccozzi, Robert C. Gallo, … Rudy Ippodrino
Journal of Translational Medicine (2020-04-22) https://doi.org/ggtzrr DOI: 10.1186/s12967-020-02344-6 · PMID: 32321524 · PMCID: PMC7174922 212.
On the origin and continuing evolution of SARS-CoV-2
Xiaolu Tang, Changcheng Wu, Xiang Li, Yuhe Song, Xinmin Yao, Xinkai Wu, Yuange Duan, Hong Zhang, Yirong Wang, Zhaohui Qian, … Jian Lu
National Science Review (2020-06) https://doi.org/ggndzn DOI: 10.1093/nsr/nwaa036 · PMCID: PMC7107875 213.
Emergence of genomic diversity and recurrent mutations in SARS-CoV-2
Lucy van Dorp, Mislav Acman, Damien Richard, Liam P. Shaw, Charlotte E. Ford, Louise Ormond, Christopher J. Owen, Juanita Pang, Cedric C. S. Tan, Florencia A. T. Boshier, … François Balloux nfection, Genetics and Evolution (2020-09) https://doi.org/ggvz4h DOI: 10.1016/j.meegid.2020.104351 · PMID: 32387564 · PMCID: PMC7199730 214.
An integrated national scale SARS-CoV-2 genomic surveillance network
The Lancet Microbe (2020-07) https://doi.org/d5mg DOI: 10.1016/s2666-5247(20)30054-9 · PMID: 32835336 · PMCID: PMC7266609 215.
Coast-to-Coast Spread of SARS-CoV-2 during the Early Epidemic in the United States
Joseph R. Fauver, Mary E. Petrone, Emma B. Hodcroft, Kayoko Shioda, Hanna Y. Ehrlich, Alexander G. Watts, Chantal B. F. Vogels, Anderson F. Brito, Tara Alpert, Anthony Muyombwe, … Nathan D. Grubaugh
Cell (2020-05) https://doi.org/gg6r9x DOI: 10.1016/j.cell.2020.04.021 · PMID: 32386545 · PMCID: PMC7204677 216.
Introductions and early spread of SARS-CoV-2 in the New York City area
Ana S. Gonzalez-Reiche, Matthew M. Hernandez, Mitchell J. Sullivan, Brianne Ciferri, Hala Alshammary, Ajay Obla, Shelcie Fabre, Giulio Kleiner, Jose Polanco, Zenab Khan, … Harm van Bakel
Science (2020-05-29) https://doi.org/gg5gv7 DOI: 10.1126/science.abc1917 · PMID: 32471856 · PMCID: PMC7259823 217.
Spread of SARS-CoV-2 in the Icelandic Population
Daniel F. Gudbjartsson, Agnar Helgason, Hakon Jonsson, Olafur T. Magnusson, Pall Melsted, Gudmundur L. Norddahl, Jona Saemundsdottir, Asgeir Sigurdsson, Patrick Sulem, Arna B. Agustsdottir, … Kari Stefansson
New England Journal of Medicine (2020-06-11) https://doi.org/ggr6wx DOI: 10.1056/nejmoa2006100 · PMID: 32289214 · PMCID: PMC7175425 218.
GISAID - Initiative
NCBI SARS-CoV-2 Resources
COVID-19 Data Portal - accelerating scientific research through data
Epidemiology, transmission dynamics and control of SARS: the 2002–2003 epidemic
Roy M. Anderson, Christophe Fraser, Azra C. Ghani, Christl A. Donnelly, Steven Riley, Neil M. Ferguson, Gabriel M. Leung, T. H. Lam, Anthony J. Hedley
Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences (2004-07-29) https://doi.org/c2n646 DOI: 10.1098/rstb.2004.1490 · PMID: 15306395 · PMCID: PMC1693389 222.
Three Emerging Coronaviruses in Two Decades
Jeannette Guarner merican Journal of Clinical Pathologymerican Journal of Clinical Pathology